Tag: GlobeNewswire

• With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028
• Phase 2 AAV izicopan program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to demonstrate the ability to replace corticosteroids
• Initial data from an investigator-initiated open-label pilot study in atypical hemolytic uremic syndrome (aHUS) anticipated in the second half of 2027
• InflaRx planning pilot study in IgA nephropathy (IgAN) to be initiated in 2027, with expected early data readout in 2028
• InflaRx announces Advisory Board comprised of leading international experts in vasculitis, nephrology and immune-mediated renal disease
• InflaRx proprietary research indicates izicopan’s product profile supports the potential for significant AAV market expansion, with an estimated peak sales potential in the range of $1.5 – 2.0 billion
• BDB-001, a vilobelimab cell line-produced antibody targeting C5a and being evaluated by InflaRx’s collaborator, Staidson BioPharmaceuticals Co., Ltd. (Staidson), is currently in a Phase 3 trial in AAV in China, with data anticipated in 2H 2028
• Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026, expected to fund ongoing operations and clinical development through 2029

Jena, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today is presenting its clinical development strategy and commercial vision for izicopan at the Company’s Capital Markets Day.

InflaRx is executing an AAV program with the goal of enabling rapid study starts and the generation of differentiating efficacy and safety data sets, which will allow the Company to continue discussions with the FDA. InflaRx expects trial site initiation to begin in early 2027 for a randomized, placebo-controlled Phase 2 study in patients with AAV with renal involvement (i.e., renal vasculitis) to assess izicopan’s ability to drive meaningful signals of clinical efficacy. The trial design has been optimized to demonstrate potential benefits related to renal function and renal injury recovery when tested in comparison to placebo, both on top of standard of care. The trial is expected to be conducted internationally, with a currently planned enrollment period of approximately 18 months.

In addition, InflaRx intends to initiate an open-label Phase 2 trial in 2027 in newly diagnosed or relapsing AAV patients in need of remission induction therapy, exploring safety and efficacy in patients when replacing glucocorticoid (GC) treatment. First data from this open-label study are expected in 2028. Given their different enrollment criteria and planned separate center selection, InflaRx does not expect the concurrent running of these studies to negatively impact speed of enrollment.

“Our Capital Markets Day underscores our conviction that izicopan has the potential to become a differentiated therapy for patients with ANCA-associated vasculitis and other renal diseases,” said Prof. Dr. Niels Riedemann, Chief Executive Officer and Founder of InflaRx. “C5aR inhibition has been clinically and commercially validated, and izicopan was specifically optimized to build on that foundation. Its rapid and sustained target inhibition, improved metabolic profile and potential for more convenient dosing support a compelling product profile. Combined with our focused development strategy, we believe izicopan is well positioned to address important unmet needs in AAV and potentially establish a broader renal-disease franchise. We have benefited from the expert guidance of the distinguished clinicians and researchers who now comprise our AAV and renal disease Advisory Board, and we look forward to continuing to work closely with them as we advance izicopan in AAV and explore its potential across additional renal diseases.”

AAV development path

To leverage the strengths of izicopan’s pharmacologic properties against the substantial unmet need that exists in AAV, InflaRx’s izicopan AAV program is targeting the generation of multiple differentiating efficacy and safety data sets in a variety of AAV settings with different strategic goals.

InflaRx expects trial site initiation to begin in early 2027 in a randomized, double-blind, placebo-controlled Phase 2 trial evaluating two izicopan doses on top of standard of care, including rituximab and GC tapering. The current design contemplates approximately 35 patients per arm and 12 months of treatment, with key data readouts occurring at 24 weeks. Efficacy assessments are expected to include disease remission, renal function, proteinuria, hematuria and renal recovery endpoints alongside safety and other efficacy assessments, as well as GC use. The enrollment period is expected to be approximately 18 months. The trial design will focus on AAV patients with defined renal involvement (renal vasculitis) and has been optimized to detect potential efficacy signals of izicopan on renal function and renal injury recovery when compared to placebo treatment.

In addition, InflaRx intends to initiate an open-label Phase 2 trial in 2027 in newly diagnosed or relapsing AAV patients in need of remission induction therapy, exploring safety and efficacy in patients when replacing GC treatment. For this, a two-stage design is planned in which a rapid taper of GC is applied in Stage 1, during remission induction therapy (e.g., in conjunction with rituximab). Upon safety assessment, a planned complete replacement strategy will be explored in Stage 2. First data from this study are expected in 2028. The trial will assess the ability of izicopan to replace GC treatment during remission induction without impacting patient safety.

This open-label trial is informed by a recently conducted Phase 1/2 trial with BDB-001, a vilobelimab cell line-produced antibody targeting C5a licensed to the Company’s Chinese partner, Staidson, in which a complete GC replacement at enrollment was successfully conducted and yielded numerically favorable remission rates when compared to the open-label control arm. The trial is further supported by external market research indicating the value that physicians ascribe to data demonstrating the ability to minimize GC use in AAV.

As currently planned, the randomized placebo-controlled Phase 2 study has been informed by first interactions with the FDA and is designed to evaluate efficacy signals focusing on renal and disease activity endpoints. InflaRx continues to evaluate options to transition as quickly as possible into registrational phase.

InflaRx continues to anticipate engaging with EMA regarding both vilobelimab and izicopan to likewise evaluate the regulatory path for InflaRx to the AAV market in that geography.

In addition, BDB-001, a vilobelimab cell line-produced antibody targeting C5a which is being evaluated by InflaRx’s collaborator Staidson, is currently in a Phase 3 trial in AAV in China, with data anticipated in 2H 2028.

Izicopan commercial potential

C5aR inhibition is an established therapeutic approach in AAV, while persistent limitations in the current standard of care create an opportunity for a next-generation therapy such as izicopan, which InflaRx believes has the potential to provide faster and deeper target inhibition, an improved safety profile (with no safety signals of concern observed to date in the 197 human subjects dosed with izicopan) and more convenient dosing. InflaRx believes izicopan has the potential to serve a greater proportion of AAV patients and to significantly expand the commercial market, with an estimated peak sales potential in the range of $1.5 – 2.0 billion, based on an independent commercial assessment.

Izicopan in broader renal disease

In addition to its efforts in AAV, InflaRx anticipates multiple proof-of-concept studies with izicopan in rare renal diseases. The Company believes izicopan’s improved pharmacologic properties are applicable to the considerable unmet needs in these areas as well, including the potential for once-daily oral dosing, lack of membrane attack complex (MAC) inhibition, and lack of vaccine requirement.

Efforts in broader renal disease include the initiation of an investigator-initiated trial (IIT) in aHUS that is expected to provide initial select patient data in 2H 2027. In addition, the Company plans to initiate a pilot study in patients with IgAN and rapidly progressive IgAN (rapidly progressive glomerulonephritis (RPGN) in IgAN patients), with initial data from patients targeted for 2028. Signal finding studies in additional rare renal disorders are contemplated as well.

To facilitate enrollment in China, a pharmacokinetic (PK) bridging study with izicopan in China is expected to have data in the first half of 2027.

AAV and renal disease advisory board

InflaRx has formed an AAV and renal disease Advisory Board, comprised of internationally recognized experts across vasculitis, nephrology, autoimmunity and immune-mediated kidney disease who have been advising the Company on its recent efforts, covering the scientific, clinical and development considerations relevant to its programs in AAV and select renal diseases. The Advisory Board is expected to provide independent expert perspectives on disease biology, patient care, clinical development and the evolving treatment landscape. Its input will help inform InflaRx’s efforts to advance complement-targeted therapeutic candidates for patients with serious inflammatory and renal diseases.

Current members of the Advisory Board include:

Professor Jonathan Barratt, PhD, FRCP
Prof. Dr. med. Jürgen Floege
Prof. Dr. med. Bernhard Hellmich
David Jayne, MD, FMedSci
Prof. Dr. med. Andreas Kronbichler
Peter A. Merkel, MD, MPH
Prof. Dr. Ming-Hui Zhao

Additional information related to the Advisory Board members, including affiliations and biographies, can be found on the InflaRx website.

InflaRx financial position

With a strong intellectual property position and an expected cash runway through 2029, InflaRx believes it is positioned to advance izicopan in AAV while selectively expanding its renal-development portfolio.

About izicopan
Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. InflaRx is planning for development of izicopan in ANCA-associated vasculitis (AAV) and additional renal indications.

In contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4/5), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7).

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the therapeutic potential of izicopan in renal and other complement-mediated diseases; the success of our future clinical trials for izicopan’s treatment of AAV and other renal diseases, including aHUS, IgAN and C3G, as well as our assessment of a broader development and registrational strategy in Europe following the revocation of the marketing authorization for Tavneos (avacopan) in the European Union, the United Kingdom and other jurisdictions, and our ability to establish proof of concept for izicopan across such indications; the timing of initiation, enrollment and data readouts of our planned Phase 2 trials of izicopan in AAV, the investigator-initiated trial in aHUS, our planned pilot study in IgAN and our PK bridging study in China; the timing, progress and results of the Phase 3 trial of BDB-001 being conducted by our collaborator Staidson in China; the timing, progress and results of preclinical studies and clinical trials of vilobelimab, izicopan and any other of our product candidates; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including potential regulatory paths in AAV for vilobelimab and izicopan and related discussions with the FDA and EMA; the timing and outcome of any discussions or submission of filings for regulatory approval of vilobelimab, izicopan or any other product candidate, and the timing of and our ability to obtain and maintain full regulatory approval and/or marketing authorization for any indication; potential strategic transactions or collaborations, including a potential partnership of izicopan or vilobelimab for PG, HS, CSU or any other indications; our expectations regarding the size of the patient populations for, the market opportunity for and the potential peak sales of izicopan, if approved; whether the FDA, EMA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; whether the results of our future clinical trials will reflect results seen in previously conducted preclinical studies and clinical trials, and the limitations of cross-study comparisons of izicopan to other product candidates or approved products, including avacopan; our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes, the optimization of our manufacturing methods and processes, and our ability to rely on existing third-party manufacturers or engage additional third-party manufacturers for planned future clinical trials and commercial supply; our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing, and the period through which our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved or authorized, any commercial sales; if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory oversight; our ability to comply with enacted and future legislation in seeking marketing approval, authorization or commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors (including avacopan) and other therapeutic products being developed in similar medical conditions in which vilobelimab, izicopan or any other of our product candidates is being developed or our industry; risks related to our reliance on foreign third-party manufacturers and suppliers, including those located in China; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo

Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b clinical study of SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT) have been published in the November 3, 2026 issue of Nature Medicine. SER-155 is an investigational, oral, cultivated multi-strain live biotherapeutic product (LBP) designed to reduce the risk of bloodstream infections (BSIs) in medically vulnerable patients. The publication reports that SER-155 was generally well tolerated and was associated with a 77% relative risk reduction in BSIs compared with placebo. SER-155 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the reduction of BSIs in adults undergoing allo-HCT, as well as Fast Track designation, and the Company has aligned with the FDA on its proposed Phase 2 study protocol. SER-155 is Phase 2-ready in allo-HCT, pending receipt of funding.

“Publication in Nature Medicine is an important milestone for the SER-155 program and recognition of the innovative science being advanced by Seres,” said Matthew Henn, Ph.D., President and Chief Scientific Officer of Seres Therapeutics. “Many bloodstream infections in transplant patients originate in the gut, when pathogens expand and cross a damaged intestinal barrier. SER-155 was designed to address both sides of that problem by preventing the colonization and expansion of pathogens, many that can harbor antibiotic resistance, in the gastrointestinal tract that results from extensive antibiotic use in these patients and also protecting and improving mucosal epithelial barrier integrity that is disrupted by conditioning cancer therapy to limit bacterial translocation from the GI into the bloodstream and potential mortality due to infection. In this study, SER-155 reduced bloodstream infections while improving biomarkers of barrier integrity and systemic inflammation, providing clinical validation of these mechanisms. We believe our live biotherapeutic approach could be highly differentiated in multiple diseases where loss of gut mucosal epithelial barrier integrity is thought to play a central role. In addition, SER-155 has the potential to address the continued emergence of antimicrobial resistant infections, particularly those in immunocompromised patients, and we thank CARB-X for their prior support of this program, our collaborators and the patients who participated in this clinical study.”

The Phase 1b study (NCT04995653) evaluated SER-155 in adults undergoing allo-HCT for hematologic malignancies. Cohort 1 was an open-label cohort that assessed safety and drug pharmacology, including engraftment of SER-155 strains in the gastrointestinal (GI) tract. Cohort 2 was a randomized, double-blind, placebo-controlled cohort that evaluated safety, drug pharmacology and clinical outcomes, including BSIs, systemic antibiotic exposure and febrile neutropenia, through day 100 after transplant.

In Cohort 2, BSIs occurred in 10% of patients receiving SER-155 compared with 42.9% of patients receiving placebo, a 77% relative risk reduction (p=0.0423). Patients receiving SER-155 also had significantly lower systemic antibiotic exposure, with a mean of 9.2 days compared with 21.1 days for placebo (p=0.0494), and a numerically lower incidence of febrile neutropenia (65% compared with 78.6%). SER-155 strains engrafted in the GI tract, and SER-155 was generally well tolerated, with no treatment-related serious adverse events observed.

Translational biomarker analyses from the study further support SER-155 mechanisms of action. Compared with placebo, SER-155 led to a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and lower plasma levels of biomarkers of systemic inflammation. SER-155 also improved biomarkers of immune homeostasis. Improved mucosal epithelial barrier integrity may reduce bacterial translocation from the GI tract into the bloodstream, consistent with the reduction in BSIs observed in the study. These barrier-protective and anti-inflammatory effects also support the potential of Seres’ LBPs in inflammatory and immune diseases, including immune checkpoint inhibitor related enterocolitis (irEC) and inflammatory bowel disease (IBD).

“These results, now peer-reviewed and published in Nature Medicine, reinforce our belief in the potential of SER-155 to prevent bloodstream infections in immunocompromised patients like allo-HCT patients,” said Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics. “We believe the ability of SER-155 to strengthen the gut barrier and reduce inflammation gives it potential well beyond transplant, including in immune checkpoint inhibitor-related enterocolitis (irEC), a serious complication of cancer immunotherapy where an immunosuppressive-free treatment could allow patients to stay on their cancer therapy.”

Seres is also developing SER-155 for irEC, a frequent and often severe adverse reaction that can force patients to interrupt or discontinue immune checkpoint inhibitor (ICI) cancer therapy and initiate immunosuppressive therapy. In July 2026, Seres reported results from an open-label investigator-sponsored trial at Memorial Sloan Kettering Cancer Center in 15 patients with Grade 2-3 irEC who had not received immunosuppressive therapy. Twelve of 15 participants (80%) achieved an immunosuppressive-free clinical response at day 15, the study’s primary endpoint, and SER-155 was generally well tolerated, with no serious adverse events assessed as related to SER-155. In the irEC study, fecal calprotectin and fecal albumin, markers of gut inflammation and mucosal barrier integrity, decreased significantly from baseline by day 43, consistent with the barrier-protective activity observed in allo-HCT.

Publication Details
Journal: Nature Medicine
Title: A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial
Publication Date & Access: November 3, 2026
Authors: Doris M. Ponce*, Zachariah DeFilipp*, Christopher B. Ford, Bina Tejura, Mary-Jane Lombardo, David I. Lichter, Meghan Chafee, Satyajit Kosuri, Nandita Khera, Hemant S. Murthy, Karamjeet S. Sandhu, David N. Fredricks, Tessa Andermann, Rajneesh Nath, Kelly Brady, Brooke R. Hasson, Emily Walsh, Nathan Hicks, Jonathan U. Peled, Lisa von Moltke, Matthew R. Henn, Marcel R.M. van den Brink**, Dennis M. Walling** and the SER-155-001 Study Team***. *These authors contributed equally. **These authors jointly supervised this work. ***A list of consortium authors and their affiliations appears at the end of the paper.

About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products in oncology that address causes of mortality and discontinuation of life-saving cancer treatment, and in inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), and is Phase 2 ready, pending receipt of funding. SER-155 is also being developed to prevent immune checkpoint inhibitor-related enterocolitis (irEC), with the aim of enabling patients to continue their ICI cancer therapy and avoid the need for immunosuppressive steroid treatment. Following promising results from an investigator-sponsored trial, Seres plans to submit the design of a study for the prevention of irEC in patients initiating ICI therapy to the FDA. The Company is advancing IND-enabling studies for SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres’ biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and overgrowth of harmful bacteria in the GI tract. For more information, please visit www.serestherapeutics.com. 

About CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is the world’s leading non-profit partnership accelerating the research and development of innovative products to prevent, diagnose and treat bacterial infections and address the global threat of antimicrobial resistance. CARB-X pairs non-dilutive funding with comprehensive technical and scientific support, resulting in supported projects being five times more likely to advance into clinical development than comparable projects that did not receive CARB-X support. Research reported in this press release is partially supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy’s Ministry of Economy and Finance (MEF), Japan’s Ministry of Health, the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or its funders

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about: SER-155 and its intended uses and benefits in allo-HCT and irEC; our clinical development plans for SER-155; the timing and results of clinical studies and data readouts; current or future product candidates and their potential impacts and outcomes; our ability to obtain funding or enter into partnerships; the anticipated timing of any of the foregoing; and other statements that are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (7) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC; (8) our novel approach to therapeutic intervention; (9) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10) our ability to achieve market acceptance necessary for commercial success; (11) the competition we will face; (12) our ability to protect our intellectual property; (13) impact of our recent management transitions and appointments and our ability to retain key personnel; and (14) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission (SEC), as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor and Media Contact:
IR@serestherapeutics.com

Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce first assay results from its 2026 diamond drill program at the Committee Bay gold project (“Committee Bay” or the “Project”), located in the eastern Kitikmeot region of Nunavut.

The 2026 drill program comprised 11 diamond drill holes totalling 4,219 metres (m), including five infill holes at the Three Bluffs deposit (Figure 1). The reported results come from infill drilling designed to increase drill density within the main portion of the existing Three Bluffs mineral resource and support improved confidence in geological and grade continuity.

Significant drill highlights, shown in true widths, include:

• Hole 26TB158 intersected 3.88 grams per tonne (“g/t”) gold (“Au”) over 17.82 m, including 18.78 g/t Au over 3.30 m
• Hole 26TB161 intersected 0.77 g/t Au over 98.60 m, including 65.60 g/t Au over 0.56 m, the widest mineralized interval drilled to date
• Hole 26TB160 intersected 0.92 g/t Au over 31.45 m, including 12.35 g/t Au over 1.18 m, and 0.99 g/t Au over 28.83 m
• Hole 26TB163 intersected 0.72 g/t Au over 36.58 m, including 2.65 g/t Au over 3.31 m
• All five holes intersected the Three Bluffs shear zone, with widths ranging from 17 m to 99 m
• 4,219 m (or 11 drill holes), including one abandoned hole, for the 2026 Committee Bay program has been completed. Assay results are pending for five of these holes, two of which are extension holes.

Results are highlighted by drill hole 26TB158, which intersected 3.88 g/t gold over 17.82 m, including a high-grade core of 18.78 g/t gold over 3.30 m, at a relatively shallow depth of 190 m. The hole was drilled within a broadly spaced area measuring 120 m by 220 m, demonstrating the continuity of mineralization across a large volume. The hole also returned a broad zone of lower-grade mineralization grading 0.39 g/t gold over 38.97 m immediately down-hole within the principal intercept (Figure 3). This intercept further demonstrates the scale and continuity of mineralization within the deposit and supports confidence in the Company’s geological model. The results are expected to be incorporated into the upcoming mineral resource update, contributing to increased resource confidence and supporting ongoing advancement of the project.

Drilling also returned broad zones of gold mineralization across the deposit, highlighted by hole 26TB161, which intersected 0.77 g/t gold over 98.60 m, including 65.60 g/t gold over 0.56 m, representing the widest mineralized interval drilled to date at Three Bluffs. Additional results include hole 26TB160, which intersected two mineralized zones grading 0.92 g/t gold over 31.45 m, including 12.35 g/t gold over 1.18 m, and 0.99 g/t gold over 28.83 m, including 3.50 g/t gold over 1.85 m (Figure 4). While hole 26TB163 returned 0.72 g/t gold over 36.58 m, including 2.65 g/t gold over 3.31 m, and hole 26TB162 returned 0.67 g/t gold over 17.36 m and 0.45 g/t gold over 20.98 m (Figure 4).

All holes disclosed in this news release, as well as the pending holes from the 2026 Committee Bay program, will be incorporated into the upcoming mineral resource estimate update for the Project. To date, 11 drill holes totalling approximately 4,219 metres have been completed, of which one hole was abandoned, and five holes are pending assay results. While the five holes reported in this release are infill holes, two of the five pending holes were designed as extension holes to define the extent of mineralization. The infill results give the Company confidence in the deposit as it continues exploring at depth and testing the full limits of the Three Bluffs resource.

“All five of our holes hit the Three Bluffs shear zone, which is exactly what this drill program was designed to confirm,” commented Tim Clark, CEO of Fury. “Hole 26TB158 stands out, returning 3.88 g/t gold over nearly 18 metres with a high-grade core of 18.78 g/t over 3.3 metres, and is a good example of the broad, continuous mineralization that has become a key differentiator of the Committee Bay project. The results strengthen our confidence in the scale of the Project as we continue to grow ounces ahead of the upcoming mineral resource update. With extension results pending, we look forward to further defining the size and potential of the Three Bluffs deposit.”

Table 1: Recent Drill Highlights

Hole ID		From (m)	To (m)	Core Length (m)	True Width (m)	Au (g/t)
26TB158		214.00	215.00	1.00	0.82	0.65
		220.00	241.60	21.60	17.82	3.88
	Incl.	233.00	237.00	4.00	3.30	18.78
		256.00	257.00	1.00	0.83	0.41
		265.00	311.00	46.00	38.97	0.39
26TB160		225.00	231.00	6.00	3.35	1.13
		248.00	303.00	55.00	31.45	0.92
	Incl.	301.00	303.00	2.00	1.18	12.35
		333.00	380.00	47.00	28.83	0.99
	Incl.	341.00	347.00	6.00	3.65	2.17
	and incl.	354.00	357.00	3.00	1.85	3.50
26TB161		230.00	408.00	178.00	98.60	0.77
	Incl.	401.00	402.00	1.00	0.56	65.60
26TB162		226.00	258.00	32.00	17.36	0.67
		272.00	310.00	38.00	20.98	0.45
26TB163		309.00	385.00	76.00	36.58	0.72
	Incl.	313.00	320.00	7.00	3.31	2.65

True widths are calculated using an interpreted mineralized domain of dip 80–89° as indicated for each hole. Reported intervals are length-weighted average gold grades. Composites require a minimum grade×thickness of 0.25 g/t·m, a minimum grade of 0.25 g/t gold and a maximum of 6 m of consecutive internal dilution; sub-intervals require a minimum grade×thickness of 5 g/t·m, a minimum grade of 2.00 g/t gold and a maximum of 2.5 m of consecutive internal dilution.

Figure 1: Committee Bay, 2026 Exploration Program Location

Figure 2: Three Bluffs – Longitudinal Section

Figure 3: Three Bluffs – Drill Hole 26TB158 Cross Section

Figure 4: Three Bluffs – Drill Hole 26TB160 Cross Section

Three Bluffs Deposit

The high-grade Three Bluffs Gold deposit is located centrally within the Committee Bay project and is estimated to contain 524,000 oz of gold in 2.1 million tonnes (Mt) at 7.85 g/t gold in the indicated mineral resource category and 720,000 oz in 2.9 Mt of gold at 7.64 g/t gold in the inferred mineral resource category (see Committee Bay NI 43-101 report “Technical Report on the Committee Bay Project, Nunavut Territory, Canada” dated September 11, 2023).

Valérie Doyon, P.Geo, VP of Geology at Fury, is a “qualified person” within the meaning of Canadian mineral projects disclosure standards instrument 43-101 and has reviewed and approved the technical disclosures in this press release.

Committee Bay Drilling QA/QC Disclosure

Intercepts at Three Bluffs were calculated using a minimum of a 2.0 g/t gold cut off at the beginning and end of the intercept and allowing for no more than 2.5 consecutive metres of less than 2.0 g/t gold. Minimum length of the composite allowed was one metre.

2026 Core (Diamond) Drilling

Analytical samples were taken by sawing NQ diameter core into equal halves on site and sent one of the halves to ALS Lab in Yellowknife, NWT for preparation and then to ALS Lab in Vancouver, BC for analysis. All samples are assayed using 50g nominal weight fire assay with atomic absorption finish (Au-AA26) and multi-element four acid digest ICP-AES/ICP-MS method (ME-MS61). QA/QC programs using internal standard samples, field and lab duplicates and blanks indicate good accuracy and precision in a large majority of standards assayed.

About Fury Gold Mines Limited

Fury Gold Mines Limited is a well-financed Canadian-focused exploration company advancing the Eau Claire gold project towards development, which holds a 5.8% equity position in Contango Silver and Gold Inc. Led by a management team and board of directors with proven success in financing and advancing exploration assets, Fury intends to grow its gold portfolio through rigorous project evaluation and exploration excellence. Fury is committed to upholding the highest industry standards for corporate governance, environmental stewardship, community engagement and sustainable mining. For more information on Fury Gold Mines, visit www.furygoldmines.com.

For further information on Fury Gold Mines Limited, please contact:

Margaux Villalpando, Investor Relations
Tel: (844) 601-0841
Email: info@furygoldmines.com
Website: www.furygoldmines.com

Forward-Looking Statements and Additional Cautionary Language

This news release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of applicable securities laws, which statements relate to the future exploration operations of the Company and may include other statements that are not historical facts. Specific forward-looking statements contained in this news release include information relating to the Company’s ongoing 2026 exploration program at the Committee Bay project and to the preparation, timing and anticipated content of an updated mineral resource estimate for the Three Bluffs deposit.

Although the Company believes that the assumptions and expectations reflected in those forward-looking statements were reasonable at the time such statements were made, there can be no certainty that such assumptions and expectations will prove to be materially correct. Mineral exploration is a high-risk enterprise.

Readers should refer to the risks discussed in the Company’s Annual Information Form and MD&A for the year ended December 31, 2025 and subsequent continuous disclosure filings with the Canadian Securities Administrators available at www.sedarplus.ca and the Company’s Annual Report available at www.sec.gov. Readers should not place heavy reliance on forward-looking information, which is inherently uncertain.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d0d10019-34cb-47bc-b5bd-961add2a7ec6

https://www.globenewswire.com/NewsRoom/AttachmentNg/5a55b537-0775-43cf-9d54-43b3603f2fc3

https://www.globenewswire.com/NewsRoom/AttachmentNg/d9c151a6-beb5-4a51-95ce-1542d5470509

https://www.globenewswire.com/NewsRoom/AttachmentNg/f9ada21c-803a-48c4-ac81-6cc201963398 

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026.

Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update.

The live webcast and archived replay of the event will be available in the Events and Presentations section of the Investors tab on the Company’s website at www.kuraoncology.com.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
gmann@kuraoncology.com

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:

Event	Guggenheim 3rd Annual Healthcare Innovation Conference
Date	Tuesday, November 10, 2026
Time	1:30 p.m. ET
Webcast	Click here
Event	2026 Jefferies Global Healthcare Conference in London
Date	Tuesday, November 17, 2026
Time	9:30 a.m. GMT
Webcast	Click here

The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com

Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.

Strong financial results and cash generation

Revenue up 4%; GAAP EPS up 18% and Adjusted EPS up 4%

Year-to-date GAAP Operating Cash Flows up 16%, Adjusted Free Cash Flow (including swaps) up 46%

Returned $748 million to shareholders year-to-date through share repurchases and dividends

BOCA RATON, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT), a leading provider of security, interactive, and smart home solutions serving residential and small business customers in the U.S., today reported results for the third quarter of 2026. Financial highlights for the third quarter are set forth below with variances on a year-over-year basis unless otherwise noted.

• Total revenue increased 4% to $1.3 billion
• Solid core operating metrics with end-of-period recurring monthly revenue (RMR) of $360 million, gross revenue attrition of 13.1%, and revenue payback at 2.3 years
• GAAP income from continuing operations of $153 million, or $0.20 per diluted share, up $9 million
• Adjusted income from continuing operations of $176 million, or $0.24 per diluted share, down $11 million
• Net cash provided by operating activities of $440 million, down $40 million; Adjusted Free Cash Flow (including interest rate swaps) of $217 million, up $8 million

“ADT delivered solid third quarter results, with revenue growth, strong year-to-date cash generation and stable core operating metrics, reflecting the durability of our business and the dedication of our more than 12,000 employees,” said ADT Chairman, President and CEO, Jim DeVries. “We are making meaningful progress in transforming ADT into a more intelligent and connected platform through investments in AI, next-generation sensing technologies, and expanded digital and retail distribution. As we look ahead to our next chapter, our focus remains on serving our customers and providing peace of mind.”

Pending Acquisition by Thrive Holdings

On October 29, 2026, the Company announced that it has entered into a definitive agreement to be acquired by Thrive Holdings in an all-cash transaction. Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, stockholders will receive $10.00 per share in cash upon completion. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions, including approval by stockholders and receipt of U.S. antitrust approval. Until the transaction closes, ADT will continue to operate independently as a public company. Following completion, ADT will become privately held, and its common stock will cease trading on the New York Stock Exchange. In consideration of the pending transaction, the Company is not providing financial guidance and is withdrawing previously issued guidance.

Business Highlights

Innovative Offerings, Unrivaled Safety and Premium Experience: The Company is undertaking focused initiatives to drive growth, strengthen brand loyalty, and improve customer acquisition efficiency while advancing its core mission of providing peace of mind. Recent progress on these initiatives is described below.

• Expanding intelligent home innovation – Introduced Unusual Activity Alerts in ADT+, leveraging connected device and sensor data to identify meaningful changes in household activity and provide proactive customer notifications.
   
• Progressing next-generation presence sensing – Advanced Origin AI-powered presence sensing capabilities, including ADT+ integration, development of future security and aging in place use cases, and commercialization planning for 2027 launch.
   
• Scaling AI across customer experience – Continued expanding AI-enabled sales and service capabilities including intelligent call routing, AI-driven inbound and outbound sales and service pilots, and more advanced transcription and agent assist capabilities to handle increasingly complex customer interactions.
   
• Broadening customer choice and market reach – Expanded ADT Blu to Walmart.com, increasing nationwide consumer access to ADT’s DIY security offering and broadening offerings across more customer segments and distribution channels.
   
• Advancing ADT+ platform across channels – Continued the phased rollout of ADT+ for dealer-generated new customer additions, extending the Company’s technology platform and supporting a more consistent customer experience across channels.
   
• Extending professional installation reach – Launched ADT Partner Services, a new offering that brings ADT’s trusted brand, field expertise and national reach to more companies and customers. Through this offering, the Company will install and service select products for Apple Retail and its customers in the U.S. beginning this fall.
   
• Strengthening community engagement impact and first responder partnerships – Expanded ADT’s signature Life Saver program with a community event in Houston and continued to support National Night Out celebrations across the country, reinforcing ADT’s commitment to safer communities.

Unlocking Shareholder Value: The Company remained focused on continuing to generate significant cash flow, enabling direct capital returns to shareholders while maintaining a healthy balance sheet.

• Share repurchases – During the third quarter, the Company repurchased and retired 3 million shares of its common stock for an aggregate price of $23 million. Year to date, the Company has repurchased and retired 89 million shares of its common stock for an aggregate price of $617 million.
   
• Enhancing financial flexibility – In August, the Company secured $100 million of incremental borrowings under the First Lien Term Loan A due 2030, further strengthening the Company’s financial flexibility.
   
• Strategic bulk account purchase – The Company completed a bulk purchase of approximately 8,000 customer accounts for $9 million cash.

Results of Operations ⁽¹⁾⁽²⁾

(in millions, except revenue payback, attrition, and per share data)		Three Months Ended September 30,
			2026				2025			Change				% Change
		GAAP
Monitoring and related services		$	1,084			$	1,098			$	(14	)		(1	)%
Security installation, product, and other			265				200				65			32	%
Total revenue		$	1,349			$	1,298			$	51			4	%
Income (loss) from continuing operations		$	153			$	144			$	9			7	%
Income (loss) from continuing operations per share – diluted		$	0.20			$	0.17			$	0.03			18	%
Net cash provided by (used in):
Operating activities		$	440			$	480			$	(40	)		(8	)%
Investing activities		$	(233	)		$	(298	)		$	65			22	%
Financing activities		$	19			$	(163	)		$	183			112	%
		Non-GAAP Measures
Adjusted EBITDA from continuing operations		$	665			$	676			$	(11	)		(2	)%
Adjusted income (loss) from continuing operations		$	176			$	187			$	(11	)		(6	)%
Adjusted EPS		$	0.24			$	0.23			$	0.01			4	%
Adjusted Free Cash Flow (including interest rate swaps)		$	217			$	208			$	8			4	%
		Other Measures
Trailing twelve-month revenue payback		2.3 years				2.3 years				— years				—	%
Trailing twelve-month gross customer revenue attrition			13.1	%			13.0	%		10 bps				N/A
RMR		$	360			$	362			$	(3	)		(1	)%

Total revenue was $1,349 million for the third quarter, up 4%. The increase was primarily driven by higher security installation, product, and other revenue due to an increase in the mix of professionally installed systems under the outright sales model. The decrease in Monitoring and related services (M&S) revenue reflects lower sales volume including the revenue loss from the October 2025 divestiture of the multifamily business, partially offset by higher average prices.

Income from continuing operations was $153 million, or $0.20 per diluted share, for the third quarter, up $9 million. This was driven by higher revenue, net of related costs, partially offset by higher selling, general, and administrative expenses, including the impact of the prior year goodwill impairment related to the divestiture of the multifamily business. Income from continuing operations also benefited from lower interest, including the impact of interest rate swaps.

Adjusted income from continuing operations was $176 million, or $0.24 per diluted share, for the third quarter, down $11 million, driven primarily by the same factors noted above excluding the prior year goodwill impairment and impact of interest rate swaps.

In addition to the factors above, earnings per share metrics benefited from a lower weighted-average diluted share count as a result of share repurchases.

Balance Sheet and Cash Flow

For the third quarter, net cash provided by operating activities was $440 million, down $40 million, primarily reflecting higher net subscriber acquisition spend related to outright sales transactions, higher general and administrative expenses, and lower M&S margins, partially offset by lower cash taxes and favorable working capital timing. Adjusted Free Cash Flow (including interest rate swaps) was $217 million, up $8 million. This measure includes the same factors above excluding the subscriber acquisition impact from the transition to an outright sales model.

In August, the Company secured $100 million of incremental borrowings under its First Lien Term Loan A due 2030, further enhancing financial flexibility and supporting general corporate purposes, which may include the repayment of a portion of the Company’s 2027 notes.

Total cash and cash equivalents as of September 30, 2026 were $228 million and no amounts were outstanding under the Company’s First Lien Revolving Credit Facility.

The Company returned $64 million of capital to shareholders during the quarter, including $23 million of share repurchases and $41 million of dividend payments. Through the end of the third quarter, the Company has repurchased 89 million shares returning $748 million to shareholders through share repurchases and dividends.

_____________________
(1)		All variances are year-over-year unless otherwise noted. The Company may sometimes present various non-GAAP and other operating measures. Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Free Cash Flow, Adjusted Free Cash Flow (including interest rate swaps), Adjusted Income (Loss), Adjusted Diluted Income (Loss) per share (or, Adjusted EPS), Net Debt, and Net Leverage Ratio are non-GAAP measures. Refer to the “Non-GAAP Measures” section for the definitions of the terms and reconciliations to the most comparable GAAP measures for those measures included herein. Operating metrics such as Gross Customer Revenue Attrition, Unit Count, RMR, Gross RMR Additions, and Revenue Payback are approximated as there may be variations to reported results in each period due to certain adjustments the Company might make in connection with the integration over several periods of acquired companies that calculated these metrics differently, or otherwise, including periodic reassessments and refinements in the ordinary course of business. These refinements, for example, may include changes due to systems conversion or historical methodology differences in legacy systems. Results of the former commercial and solar businesses are presented as discontinued operations. Except for cash flow measures, and unless otherwise noted, amounts herein reflect the results of the Company’s continuing operations only.
(2)		Amounts may not sum due to rounding.

Conference Call

As previously announced, management will host a conference call at 10 a.m. ET today to discuss the Company’s third quarter 2026 results. In consideration of the proposed acquisition of ADT by Thrive Holdings announced on October 29, 2026, the Company will not be taking questions on the call.  Participants may listen to a live webcast through the investor relations website at investor.adt.com. Alternatively, participants may listen to the live call by dialing 1-833-461-5787 (toll-free) or 1-585-542-9983 and providing the access code 472959920. A replay of the webcast will be available on the website within 24 hours after the event.

A slide presentation highlighting the Company’s results will also be available on the Investor Relations section of the Company’s website. From time to time, the Company may use its website as a channel of distribution of material Company information. Financial and other material information regarding the Company is routinely posted on and accessible at investor.adt.com.

About ADT Inc.

ADT is a leading provider of security, interactive, and smart home solutions serving residential and small business customers in the U.S. Through innovative offerings, unrivaled safety, and a premium customer experience delivered by the largest network of smart home security professionals in the U.S., ADT empowers people to protect and connect to what matters most, every second, every day. For more information, visit www.adt.com.

Forward-Looking Statements

ADT has made statements in this press release that are forward-looking and therefore subject to risks and uncertainties, including those described below. All statements, other than statements of historical fact, included in this document are, or could be, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and are made in reliance on the safe harbor protections provided thereunder. These forward-looking statements relate to, among other things, the Company’s capital allocation priorities and commitments; the Company’s partnership programs and the bulk purchase of customer accounts; initiatives with respect to the Company’s products and services, including ADT+, ADT Blu, Origin AI’s presence sensing technology, and the expected benefits and capabilities of such products and services; the Company’s ability to successfully execute and scale its DIY offerings, including through the expansion of its retail and e-commerce distribution channels; the Company’s development, deployment, and integration of AI in its products, services, and operations, including AI-driven customer interactions, virtual agents, operational efficiencies, and home intelligence capabilities; and the expectations, plans and objectives of management; any stated or implied outcomes with regard to the foregoing; and other matters. Without limiting the generality of the preceding sentences, any time we use the words “ongoing,” “expects,” “intends,” “will,” “anticipates,” “believes,” “confident,” “possible,” “continue,” “propose,” “seeks,” “could,” “may,” “should,” “estimates,” “forecasts,” “might,” “potential,” “outlook,” “goals,” “objectives,” “targets,” “planned,” “projects,” and, in each case, their negative or other various or comparable terminology, and similar expressions, we intend to clearly express that the information deals with possible future events and is forward-looking in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. We caution that these statements are subject to risks and uncertainties, many of which are outside of the Company’s control and could cause future events or results to be materially different from those stated or implied in this press release, including, among others, the risk that the proposed transaction with Thrive Holdings announced on October 29, 2026 (the “Proposed Merger”) may not be completed in a timely manner or at all; the failure to receive, on a timely basis or otherwise, the required approvals of the Proposed Merger by the Company’s stockholders; the possibility that any or all of the various conditions to the consummation of the Proposed Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the possibility that competing offers or acquisition proposals for the Company will be made; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the Proposed Merger, including in circumstances which would require the Company to pay a termination fee; the effect of the announcement or pendency of the Proposed Merger on the Company’s ability to attract, motivate or retain key executives and employees, its ability to maintain relationships with its customers, suppliers and other business counterparties, or its operating results and business generally; risks related to the Proposed Merger diverting management’s attention from the Company’s ongoing business operations; the risk of stockholder litigation in connection with the Proposed Merger, including resulting expense or delay; risks and uncertainties related to the Company’s divestiture of its commercial business (the “Commercial Divestiture”) and the Company’s exit from its residential solar business (the “ADT Solar Exit”); the Company’s ability to successfully integrate the acquisition of Origin AI and realize expected benefits of the acquisition; the Company’s ability to execute on transformation initiatives, including technology initiatives related to artificial intelligence and whole-home intelligence; the Company’s ability to maintain and grow the Company’s existing customer base, including the conversion of customers who continue to utilize outdated technology, and to integrate strategic bulk purchases of customer accounts; the impact of cyber attacks or related breaches with respect to information technology systems, cybersecurity, or data security involving the Company, our business partners, or other third parties whose systems are interconnected with ours, and any future or still undetected attacks or incidents; any material changes to the valuation allowances the Company takes with respect to its deferred tax assets; any changes in regulations or laws, global, economic, sovereign, political, or financial conditions, including labor and tax law changes or any impacts on the global economy or consumer discretionary spending due to tariffs or otherwise, changes to privacy requirements, changes to telemarketing, email marketing and similar consumer protection laws, interest rate volatility, and trade tariffs and restrictions applicable to the products we sell; the Company’s dependence on third-party providers, suppliers, dealers, and retail partners to enable it to produce and distribute its products and services in a cost-effective manner that protects the Company’s brand; the Company’s ability to effectively implement its strategic partnership with, and utilize any of the amounts invested by, Google; the Company’s ability to expand ADT+ and achieve expected adoption and customer engagement; risks related to the Company’s use of AI in its products, services, and operations, including evolving legal and regulatory requirements, technological limitations, potential liability, and reputational concerns; the expected shift in the Company’s transaction mix (including increased outright equipment sales) and the related effects on the timing and mix of revenue and costs; and risks that are described in the Company’s most recently filed Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in those reports, and in the Company’s other filings with the SEC. Any forward-looking statement made in this press release speaks only as of the date on which it is made. ADT undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, unless required by law.

ADT INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) (Unaudited)
		Three Months Ended September 30,														Nine Months Ended September 30,
			2026				2025			$ Change				% Change			2026				2025			$ Change				% Change
Revenue:
Monitoring and related services		$	1,084			$	1,098			$	(14	)		(1)%		$	3,246			$	3,271			$	(25	)		(1)%
Security installation, product, and other			265				200				65			32%			693				582				112			19%
Total revenue			1,349				1,298				51			4%			3,940				3,852				87			2%
Cost of revenue (exclusive of depreciation and amortization shown separately below):
Monitoring and related services			160				162				(2	)		(1)%			472				482				(10	)		(2)%
Security installation, product, and other			133				89				44			50%			327				259				68			26%
Total cost of revenue			293				251				42			17%			799				741				58			8%
Selling, general, and administrative expenses			400				384				16			4%			1,151				1,109				42			4%
Depreciation and intangible asset amortization			345				348				(3	)		(1)%			1,038				1,026				12			1%
Operating income (loss)			311				315				(5	)		(1)%			952				976				(24	)		(3)%
Interest expense, net			(102	)			(113	)			11			(10)%			(302	)			(349	)			47			(13)%
Other income (expense)			—				(4	)			4			N/M			3				(8	)			11			N/M
Income (loss) from continuing operations before income taxes			209				199				11			5%			653				619				34			5%
Income tax benefit (expense)			(57	)			(55	)			(1	)		3%			(175	)			(165	)			(11	)		6%
Income (loss) from continuing operations			153				144				9			7%			477				454				23			5%
Income (loss) from discontinued operations, net of tax			(2	)			2				(4	)		N/M			(4	)			(4	)			(1	)		22%
Net income (loss)		$	151			$	145			$	5			4%		$	473			$	451			$	22			5%
Common Stock:
Income (loss) from continuing operations per share – basic		$	0.21			$	0.18									$	0.62			$	0.54
Income (loss) from continuing operations per share – diluted		$	0.20			$	0.17									$	0.59			$	0.51
Net income (loss) per share – basic		$	0.21			$	0.18									$	0.62			$	0.54
Net income (loss) per share – diluted		$	0.19			$	0.16									$	0.57			$	0.50
Weighted-average shares outstanding – basic			676				765										714				783
Weighted-average shares outstanding – diluted			737				828										774				846
Class B Common Stock:
Income (loss) from continuing operations per share – basic		$	0.21			$	0.18									$	0.62			$	0.54
Income (loss) from continuing operations per share – diluted		$	0.20			$	0.17									$	0.59			$	0.51
Net income (loss) per share – basic		$	0.21			$	0.18									$	0.62			$	0.54
Net income (loss) per share – diluted		$	0.19			$	0.16									$	0.57			$	0.50
Weighted-average shares outstanding – basic			55				55										55				55
Weighted-average shares outstanding – diluted			55				55										55				55

^{Note: amounts may not sum due to rounding}

ADT INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) (Unaudited)
	September 30, 2026			December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	228		$	81
Restricted cash and restricted cash equivalents		26			28
Accounts receivable, net		373			385
Inventories, net		177			202
Prepaid expenses and other current assets		163			250
Total current assets		967			946
Property and equipment, net		288			243
Subscriber system assets, net		2,630			2,791
Intangible assets, net		4,769			4,818
Goodwill		4,992			4,886
Deferred subscriber acquisition costs, net		1,553			1,452
Other assets		753			683
Total assets	$	15,953		$	15,819
Liabilities and stockholders’ equity
Current liabilities:
Current maturities of long-term debt	$	1,242		$	310
Accounts payable		163			107
Deferred revenue		245			244
Accrued expenses and other current liabilities		423			352
Total current liabilities		2,073			1,013
Long-term debt		6,539			7,379
Deferred subscriber acquisition revenue		2,028			2,084
Deferred tax liabilities		1,316			1,267
Other liabilities		358			297
Total liabilities		12,312			12,040
Total stockholders’ equity		3,640			3,779
Total liabilities and stockholders’ equity	$	15,953		$	15,819

^{Note: amounts may not sum due to rounding}

ADT INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions)  (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Cash flows from operating activities:
Net income (loss)	$	151			$	145			$	473			$	451
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and intangible asset amortization		345				348				1,038				1,026
Amortization of deferred subscriber acquisition costs		71				64				207				187
Amortization of deferred subscriber acquisition revenue		(88	)			(90	)			(267	)			(268	)
Share-based compensation expense		19				11				51				43
Deferred income taxes		7				44				24				46
Provision for losses on receivables and inventory		52				55				170				156
Loss on extinguishment of debt		—				5				—				11
Goodwill, intangible, and other asset impairments		—				14				—				15
Unrealized (gain) loss on interest rate swap contracts		9				15				26				57
Other non-cash items, net		22				14				55				53
Changes in operating assets and liabilities, net of effects of acquisitions and dispositions:
Deferred subscriber acquisition costs		(115	)			(99	)			(309	)			(288	)
Deferred subscriber acquisition revenue		41				58				139				173
Other, net		(72	)			(103	)			137				(151	)
Net cash provided by (used in) operating activities		440				480				1,745				1,511
Cash flows from investing activities:
Dealer generated customer accounts and bulk account purchases		(124	)			(157	)			(363	)			(488	)
Subscriber system asset expenditures		(65	)			(98	)			(234	)			(307	)
Purchases of property and equipment		(46	)			(43	)			(141	)			(126	)
Acquisition of businesses, net of cash acquired		—				—				(164	)			—
Proceeds (payments) from interest rate swaps		1				(1	)			2				(2	)
Other investing, net		—				—				—				2
Net cash provided by (used in) investing activities		(233	)			(298	)			(900	)			(921	)
Cash flows from financing activities:
Proceeds from long-term borrowings		115				610				364				1,340
Repayment of long-term borrowings, including call premiums		(27	)			(627	)			(274	)			(1,278	)
Proceeds from receivables facility		51				60				155				207
Repayment of receivables facility		(63	)			(59	)			(193	)			(174	)
Proceeds (payments) from interest rate swaps		15				17				39				51
Repurchases of common stock, including excise tax		(23	)			(112	)			(623	)			(607	)
Dividends on common stock		(41	)			(46	)			(130	)			(142	)
Payments on finance leases		(8	)			(6	)			(23	)			(21	)
Other financing, net		—				—				(13	)			—
Net cash provided by (used in) financing activities		19				(163	)			(699	)			(623	)
Cash and cash equivalents and restricted cash and restricted cash equivalents:
Net increase (decrease)		227				19				146				(33	)
Beginning balance		28				152				109				204
Ending balance	$	255			$	171			$	255			$	171

Note: amounts may not sum due to rounding

ADT INC. AND SUBSIDIARIES
NON-GAAP MEASURES

ADT sometimes uses information (“non-GAAP financial measures”) that is derived from the consolidated financial statements, but that is not presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”). Under SEC rules, non-GAAP financial measures may be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for or superior to GAAP results.

The following information includes definitions of the Company’s non-GAAP financial measures used in this release, reasons management believes these measures are useful to investors regarding the Company’s financial condition and results of operations, additional purposes, if any, for which management uses the non-GAAP financial measures, and limitations to using these non-GAAP financial measures, as well as reconciliations of these non-GAAP financial measures to the most comparable GAAP measures. Each non-GAAP financial measure is presented following the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. The limitations of non-GAAP financial measures are best addressed by considering these measures in conjunction with the appropriate GAAP measures. In addition, computations of these non-GAAP measures may not be comparable to other similarly titled measures reported by other companies.

Unless otherwise noted, non-GAAP measures herein reflect the results of the Company’s continuing operations.

Free Cash Flow, Adjusted Free Cash Flow, and Adjusted Free Cash Flow including interest rate swaps

The Company defines Free Cash Flow as cash flows from operating activities less cash outlays related to capital expenditures. The Company defines capital expenditures to include accounts purchased through the Company’s network of authorized dealers or third parties outside of the Company’s authorized dealer network, subscriber system asset expenditures, and purchases of property and equipment. These items are subtracted from cash flows from operating activities because they represent long-term investments that are required for normal business activities.

The Company defines Adjusted Free Cash Flow as Free Cash Flow adjusted for net cash flows related to (i) net proceeds or payments from the Company’s consumer receivables facility; (ii) restructuring and integration payments; (iii) integration-related capital expenditures; and (iv) transaction costs and other payments or receipts that may mask operating results or business trends. Adjusted Free Cash Flow including interest rate swaps reflects Adjusted Free Cash Flow plus net cash settlements on interest rate swaps presented outside of net cash provided by (used in) operating activities.

The Company believes the presentations of these non-GAAP measures are appropriate to provide investors with useful information about the Company’s ability to repay debt, pay dividends, repurchase shares, and make other investments. The Company believes the presentation of Adjusted Free Cash Flow is also a useful measure of the cash flow attributable to normal business activities, inclusive of the net cash flows associated with the acquisition of subscribers, as well as the Company’s ability to repay debt, pay dividends, repurchase shares, and make other investments. Further, Adjusted Free Cash Flow including interest rate swaps is a useful measure of Adjusted Free Cash Flow inclusive of all cash interest.

There are material limitations to using these non-GAAP measures. These non-GAAP measures adjust for cash items that are ultimately within management’s discretion to direct, and therefore, may imply that there is less or more cash available than the most comparable GAAP measure. These non-GAAP measures are not intended to represent residual cash flow for discretionary expenditures since debt repayment requirements and other non-discretionary expenditures are not deducted.

	Three Months Ended September 30,								Nine Months Ended September 30,
(in millions)		2026				2025				2026				2025
Net cash provided by (used in):
Operating activities	$	440			$	480			$	1,745			$	1,511
Investing activities	$	(233	)		$	(298	)		$	(900	)		$	(921	)
Financing activities	$	19			$	(163	)		$	(699	)		$	(623	)
Net cash provided by (used in) operating activities	$	440			$	480			$	1,745			$	1,511
Dealer generated customer accounts and bulk account purchases		(124	)			(157	)			(363	)			(488	)
Subscriber system asset expenditures		(65	)			(98	)			(234	)			(307	)
Purchases of property and equipment		(46	)			(43	)			(141	)			(126	)
Free Cash Flow		206				182				1,007				590
Net proceeds (payments) from receivables facility		(11	)			1				(38	)			33
Merger, restructuring and integration payments(1)		4				2				17				10
Other, net(2)		3				6				10				26
Adjusted Free Cash Flow	$	201			$	192			$	996			$	659
Interest rate swaps presented outside operating activities		15				16				41				49
Adjusted Free Cash Flow (including interest rate swaps)	$	217			$	208			$	1,037			$	709

^{Note: amounts may not sum due to rounding
_______________________
(1)   During 2026, primarily includes payments related to the Origin AI Acquisition.
(2)   For 2025, primarily includes net outflows related to the former Solar Business and third-party costs associated with implementation of a new ERP system that the Company will not continue to incur once the ERP system is fully implemented.}

Adjusted EBITDA from Continuing Operations (“Adjusted EBITDA”) and Adjusted EBITDA Margin from Continuing Operations (“Adjusted EBITDA Margin”)

The Company defines Adjusted EBITDA as income (loss) from continuing operations adjusted for (i) interest; (ii) taxes; (iii) depreciation and amortization, including depreciation of subscriber system assets and other fixed assets and amortization of dealer and other intangible assets; (iv) amortization of deferred costs and deferred revenue associated with subscriber acquisitions; (v) share-based compensation expense; (vi) merger, restructuring, integration, and other items; (vii) impairment charges; and (viii) other non-cash or non-routine adjustments not necessary to operate our business.

The Company believes Adjusted EBITDA is useful to investors to measure the operational strength and performance of its business. The Company believes the presentation of Adjusted EBITDA is useful as it provides investors additional information about operating profitability adjusted for certain non-cash items, non-routine items the Company does not expect to continue at the same level in the future, as well as other items not core to its operations. Further, the Company believes Adjusted EBITDA provides a meaningful measure of operating profitability because the Company uses it for evaluating business performance, making budgeting decisions, and comparing company performance against other peer companies using similar measures.

There are material limitations to using Adjusted EBITDA as it does not include certain significant items which directly affect income (loss) from continuing operations (the most comparable GAAP measure).

The discussion above is also applicable to Adjusted EBITDA margin, which is calculated as Adjusted EBITDA as a percentage of total revenue.

	Three Months Ended September 30,
(in millions)		2026				2025
Income (loss) from continuing operations	$	153			$	144
Interest expense, net		102				113
Income tax expense (benefit)		57				55
Depreciation and intangible asset amortization		345				348
Amortization of deferred subscriber acquisition costs		71				64
Amortization of deferred subscriber acquisition revenue		(88	)			(90	)
Share-based compensation expense		19				11
Merger, restructuring, integration and other(1)		2				6
Goodwill impairment(2)		—				12
Unrealized gain (loss) on interest rate swaps(3)		5				4
Loss on extinguishment of debt		—				5
Other, net(4)		1				5
Adjusted EBITDA	$	665			$	676
Income (loss) from continuing operations to total revenue ratio		11	%			11	%
Adjusted EBITDA Margin (as percentage of Total Revenue)		49	%			52	%

^{Note: amounts may not sum due to rounding
_______________________
(1)   During 2026, primarily relates to the Origin AI Acquisition and restructuring expenses.
(2)   Represents a goodwill impairment charge associated with the Multifamily Divestiture.
(3)   Includes the unrealized gain or loss on interest rate swaps presented in other income (expense).
(4)   During 2025, primarily includes one-time costs associated with debt transactions.}

Adjusted Income (Loss) from Continuing Operations (“Adjusted Income (Loss)”) and Adjusted Diluted Income (Loss) per Share from Continuing Operations (“Adjusted Diluted Income (Loss) per Share” or “Adjusted EPS”)

The Company defines Adjusted Income (Loss) as income (loss) from continuing operations adjusted for (i) share-based compensation expense; (ii) merger, restructuring, integration, and other items; (iii) impairment charges; (iv) unrealized (gains) or losses on interest rate swaps; (v) other non-cash or non-routine adjustments not necessary to operate our business; and (vi) the impact these items have on taxes.

The Company defines Adjusted EPS as diluted income (loss) from continuing operations per share adjusted for the per share amounts related to (i) share-based compensation expense; (ii) merger, restructuring, integration, and other items; (iii) impairment charges; (iv) unrealized (gains) or losses on interest rate swaps; (v) other non-cash or non-routine adjustments not necessary to operate our business; and (vi) the impact these items have on taxes.

Adjusted EPS equals Adjusted Income (Loss) divided by diluted weighted-average shares outstanding of common stock as calculated in accordance with GAAP. When the control number for the GAAP calculation is negative, diluted weighted-average shares outstanding of common stock does not include the assumed conversion of Class B common stock and other potential shares, such as share-based compensation awards, to shares of common stock.

The Company believes Adjusted Income (Loss) and Adjusted EPS are benchmarks used by analysts and investors who follow the industry for comparison of our performance with other companies in the industry, although these measures may not be directly comparable to similar measures reported by other companies. The Company believes the presentation of Adjusted EPS is useful to investors as it provides additional information about how our management evaluates the business. Management and the Board also use Adjusted EPS to evaluate the performance of employees (including members of management) and the Company as a whole, as well as to allocate resources.

There are material limitations to using these measures, as they do not reflect certain significant items which directly affect income (loss) from continuing operations and related per share amounts (the most comparable GAAP measures).

	Three Months Ended September 30,
(in millions, except per share data)		2026				2025
Income (loss) from continuing operations	$	153			$	144
Share-based compensation expense		19				11
Merger, restructuring, integration, and other(1)		2				6
Goodwill impairment(2)		—				12
Interest rate swaps, net(3)		9				15
Loss on extinguishment of debt		—				5
Other, net		1				5
Tax adjustments(4)		(7	)			(11	)
Adjusted Income (Loss) from continuing operations	$	176			$	187
Diluted weighted-average shares outstanding of Common Stock(5):		737				828
Diluted income (loss) from continuing operations per share of Common Stock	$	0.20			$	0.17
Share-based compensation expense		0.03				0.01
Merger, restructuring, integration, and other(1)		—				0.01
Goodwill impairment(2)		—				0.01
Interest rate swaps, net(3)		0.01				0.02
Loss on extinguishment of debt		—				0.01
Other, net(6)		0.01				0.01
Tax adjustments(4)		(0.01	)			(0.01	)
Adjusted EPS	$	0.24			$	0.23

^{Note: amounts may not sum due to rounding.
_______________________
(1)   During 2026, primarily relates to the Origin AI Acquisition and restructuring expenses.
(2)   Represents a goodwill impairment charge associated with the Multifamily Divestiture.
(3)   Primarily includes unrealized (gains) or losses on interest rate swaps presented in interest expense, net and other income (expense).
(4)   Represents the tax impact on adjustments using the federal and state blended statutory rate.
(5)  Refer to the Company’s Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K for further discussion regarding the computation of diluted weighted-average shares outstanding of Common Stock.
(6)   Includes the impact related to the two-class method of EPS. Refer to the Company’s Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.}

CONTACT: Investor Relations:
investorrelations@adt.com
Tel: 888-238-8525

Media Relations:
media@adt.com

In its first run on a real quantum processor, Quantum X Labs’ Qatacomb scheme successfully recovered an encrypted image using a 156-qubit machine, while an adversary without the key gained no usable information in the demonstration, illustrating a privacy guarantee designed to hold regardless of an adversary’s computing power

TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”), a dual-listed technology company, today announced that Quantum X Labs Inc. (Nasdaq: QXL) (“Quantum X Labs” or “QXL”), in which Gix holds approximately 13% (2,818,585 shares), has reported the first demonstration of its Qatacomb quantum encryption scheme on commercial quantum hardware.

In a run on an IBM Quantum Heron r2 processor, programmed through IBM’s open-source Qiskit framework, the intended recipient reconstructed an encrypted image by reading through the machine’s own noise, while an adversary who did not hold the key gained no usable information about the message.

Quantum X Labs believes the significance lies in the kind of guarantee the scheme is designed to provide. Most encryption in use today rests on mathematical problems that are hard to solve with current computers, and a sufficiently capable quantum computer is widely expected to be able to break much of it. Qatacomb is instead designed so that its privacy follows from the structure of quantum states themselves: it is intended to be information-theoretic, meaning its security is not designed to depend on any assumption about how much computing power an adversary can bring to bear, now or in the future.

The demonstration moves Qatacomb from theory to testing on a real device. The intended recipient, holding the key, recovered the correct content for better than nine of every ten image elements and reconstructed the full image without error – despite the processor’s real noise. The adversary’s best possible measurement, evaluated exactly, returned no usable advantage.

About Gix Internet Ltd.

Gix Internet Ltd. is a technology company that is listed on the Nasdaq Capital Market under the symbol GIXI and on the Tel Aviv Stock Exchange under the symbol GIX. Its operating focus is deliverz.ai, a wholly-owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

About Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended security and privacy characteristics of Qatacomb, including its intended information-theoretic security and its design not to depend on assumptions regarding an adversary’s computing power; the potential significance, capabilities, benefits and applications of Qatacomb and QXL’s quantum encryption technologies; and QXL’s continued development, testing and commercialization of Qatacomb and its other quantum technologies. There can be no assurance that any benefit realized by QXL will result in any corresponding benefit to the Company or the value of its investment in QXL. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. For a description of risks affecting QXL, reference is made to QXL’s filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites. IBM, IBM Quantum and the names of IBM quantum processors are trademarks of International Business Machines Corporation; IBM is not affiliated with, and has not endorsed, Gix, QXL or the results described in this press release.

Investor Relations Contact:
Michal Efraty
Investor Relations
michal@efraty.com

• Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan
• Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval

• Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer

• Launched variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season in multiple regions worldwide

• Third quarter 2026 revenues of €1,289.2 million¹, adjusted² R&D expenses of €578.5 million (IFRS R&D expenses of €748.1 million), and adjusted SG&A³ expenses of €178.5 million

• Raised full-year 2026 revenue guidance midpoint and updated range to €1.7–1.9 billion, and maintained strong financial position with cash, cash equivalents and security investments of €16.2 billion⁴

Conference call and webcast scheduled for November 3, 2026, at 8:00 a.m. EST (2:00 p.m. CET)

MAINZ, Germany, November 3, 2026 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and nine months ended September 30, 2026 and provided an update on its corporate progress.

“As 2026 draws to a close, the achievement of numerous important milestones throughout the year demonstrates our commitment to advancing our oncology pipeline, and our combination therapy strategy continues to gain momentum, underscored by the announced first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. “With a growing pipeline, key registrational trials, strategic partnerships, and financial strength, BioNTech is well positioned for its next phase of growth as we advance toward becoming a diversified, multi-product company by 2030.”

Financial Review for Third Quarter and Year-to-Date 2026

in millions €, except per share data	Third Quarter 2026		Third Quarter 2025
	IFRS Results	Adjusted Results2	IFRS Results	Adjusted Results2
Revenues	1,289.2	1,289.2	1,518.9	1,518.9
Net profit / (loss)	184.5	440.9	(28.7)	752.5
Diluted profit / (loss) per share	0.73	1.76	(0.12)	3.11
Weighted average number of shares outstanding (in millions)5	251	251	241	242

in millions €, except per share data	Year-to-date 2026		Year-to-date 2025
	IFRS Results	Adjusted Results2	IFRS Results	Adjusted Results2
Revenues	1,512.9	1,512.9	1,962.5	1,962.5
Net loss	(1,168.2)	(615.9)	(831.1)	(27.1)
Diluted loss per share	(4.63)	(2.44)	(3.45)	(0.11)
Weighted average number of shares outstanding (in millions)5	252	252	241	241

The figures below compare the third quarter of 2026 and the year-to-date period ended September 30, 2026, to the corresponding prior year periods, except where noted.

Revenues were €1,289.2 million for the third quarter of 2026, compared to €1,518.9 million. Year-to-date revenues were €1,512.9 million, compared to €1,962.5 million. The decreases were primarily driven by expected lower market demand for BioNTech’s COVID-19 vaccines.

Research and development (“R&D”) expenses were €748.1 million for the third quarter of 2026, compared to €564.8 million. Year-to-date R&D expenses were €1,856.1 million, compared to €1,599.5 million. R&D expenses were mainly driven by higher expenses for the development of BioNTech’s late-stage immuno-oncology (“IO”) and antibody-drug conjugate (“ADC”) programs and impairment expenses related to intangible assets which are outside of BioNTech’s strategic focus.

Adjusted R&D expenses were €578.5 million for the third quarter of 2026, compared to €479.4 million. Year-to-date adjusted R&D expenses were €1,582.7 million, compared to €1,514.1 million. Adjusted R&D expenses for both the third quarter and year-to-date period in 2026 exclude impairment expenses related to intangible assets which are outside of BioNTech’s strategic focus.

Sales, general and administrative (“SG&A”) expenses were €178.5 million for the third quarter of 2026, compared to €148.5 million. Year-to-date SG&A expenses were €527.1 million, compared to €406.5 million. The increases were mainly driven by the ongoing pre‑launch activities and commercial build-up, expenses associated with BioNTech’s global initiative on scaling processes and ERP infrastructure to strengthen operational execution and the inclusion of operations from CureVac. This was partly offset by cost reductions resulting from the execution of initiatives related to BioNTech’s pipeline prioritization.

Other operating result was negative €134.3 million for the third quarter of 2026, compared to negative €704.2 million. Year-to-date other operating result was negative €358.6 million, compared to negative €730.1 million. The quarterly and year-to-date results were primarily driven by impairment losses and employee related restructuring costs derived from BioNTech’s pipeline prioritization execution.

Adjusted other operating result was negative €58.9 million for the third quarter of 2026, compared to negative €8.4 million. Year-to-date adjusted other operating result was negative €91.1 million, compared to negative €11.5 million. Adjusted other operating result for the third quarter of 2026 excludes impairment losses and employee-related costs related to BioNTech’s pipeline prioritization execution as well as settlement expenses, while the comparable prior year result excludes employee-related costs and settlement expenses. Year-to-date periods in 2026 and 2025 exclude impairment losses, employee-related costs and settlement expenses, while 2025 also excludes a bargain purchase.

Net profit was €184.5 million for the third quarter of 2026, compared to a net loss of €28.7 million. Year-to-date net loss was €1,168.2 million, compared to a net loss of €831.1 million.

Adjusted net profit was €440.9 million for the third quarter of 2026, compared to an adjusted net profit of €752.5 million. Year-to-date adjusted net loss was €615.9 million, compared to an adjusted net loss of €27.1 million.

Diluted profit per share was €0.73 for the third quarter of 2026, compared to a diluted loss per share of €0.12. Year-to-date diluted loss per share was €4.63, compared to a diluted loss per share of €3.45.

Adjusted diluted profit per share was €1.76 for the third quarter of 2026, compared to adjusted diluted profit per share of €3.11. Year-to-date adjusted diluted loss per share was €2.44, compared to an adjusted diluted loss per share of €0.11.

Cash, cash equivalents and security investments as of September 30, 2026 were €16,163.8 million, comprising €10,200.8 million in cash and cash equivalents, €4,390.2 million in current security investments disclosed as financial assets and €1,572.8 million in non-current security investments disclosed as financial assets.

Shares outstanding as of September 30, 2026 were 247,928,180, excluding 11,099,307 shares held in treasury.

In May 2026, BioNTech entered into a share repurchase program, pursuant to which the Company may purchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, in the amount of up to $1.0 billion until and including May 6, 2027. Since the inception of the program through September 30, 2026, 5,037,452 ADSs were repurchased at an average price of $91.98 (€80.10), for total consideration of $463.3 million (€403.5 million).

“Our performance in the third quarter allowed us to narrow our full-year 2026 revenue guidance to the upper end of the previous guidance range,” said Ramón Zapata, Chief Financial Officer at BioNTech. “Fueled by our financial strength, we continue to focus our investments on our prioritized late-stage oncology programs. While we further enhance our operational efficiency and cost discipline, we return capital to shareholders through our share repurchase program. Together, these steps are aimed at creating sustainable long-term value.”

Updated 2026 Financial Year Guidance⁶:

	FY 2026 non-IFRS Guidance
	Current Nov. 3, 2026	Prior Aug. 4, 2026
Revenues	€1,700 – €1,900 million	€1,600 – €1,900 million
Adjusted R&D expenses	Unchanged	€2,000 – €2,300 million
Adjusted SG&A expenses3	Unchanged	€700 – €800 million

BioNTech is raising the midpoint of its previously provided full-year 2026 revenue guidance. The updated guidance follows the Company’s revenue performance in the third quarter. The guidance for adjusted R&D expenses as well as adjusted SG&A expenses remains unchanged.

BioNTech exercised an option in the existing collaboration agreement with Roche/Genentech where, under the terms of the agreement, future R&D costs related to the program will be generally assigned to Roche/Genentech effective January 1, 2027, while BioNTech will be eligible to receive royalties in case of successful development and commercialization.

The updated terms pursuant to the exercised option under the existing agreement align with BioNTech’s broader capital allocation framework and will not affect the ongoing pancreatic ductal adenocarcinoma (“PDAC”) trial, which will continue as planned.

While this decision follows the regular assessment of the financial structure of existing collaborations, BioNTech’s broader commitment to mRNA and its potential in oncology remains unchanged. Its conviction in mRNA is anchored by over a decade of translational and clinical research, as well as deep experience in the field. BioNTech continues to advance mRNA cancer immunotherapies and invest in them as a key pillar of its oncology strategy, including novel combination approaches intended to maximize the potential of its diversified oncology pipeline.

The full interim unaudited condensed consolidated financial statements can be found in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed today with the United States Securities and Exchange Commission (“SEC”) and available at www.sec.gov.

Endnotes
¹  All numbers in this press release have been rounded.
² In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of the Company’s business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov. The weighted average number of shares outstanding is excluded from that reconciliation. While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside the Company’s financial statements prepared in accordance with IFRS Accounting Standards. Unless otherwise indicated, Adjusted Results are identical to IFRS Results.
³  Sales, general and administrative expenses (“SG&A”) include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses.
⁴  As of September 30, 2026.
⁵ Only basic EPS are calculated in loss making periods. Diluted EPS include outstanding instruments from BioNTech’s share-based payment programs. The weighted average number of shares outstanding is determined as described in BioNTech’s Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended and is not adjusted by non-IFRS measures.
⁶  Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov.
⁷  An overview of abbreviations of target structures and indications is compiled in a directory at the end of this press release.

Variant-adapted COVID-19 Vaccine
 
In the third quarter of 2026, BioNTech and Pfizer executed the commercial launch of their variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season.

• In July 2026, BioNTech and Pfizer’s monovalent XFG-adapted COVID-19 vaccine was approved by the European Commission following recommendation for marketing authorization by the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”). The companies began shipments of the vaccine after approval to ensure rapid access of the season’s vaccine.
• In August 2026, the United States Food and Drug Administration (“FDA”) approved the supplemental Biologics License Application (“sBLA”) for BioNTech and Pfizer’s monovalent XFG-adapted COVID-19 vaccine for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. The new variant-adapted COVID-19 vaccine was shipped immediately following approval and was made available in pharmacies, hospitals, and clinics across the United States.

Select Oncology Pipeline Updates

Next-Generation Immunomodulators and Combinations

Pumitamig (BNT327/BMS986545) is an investigational bispecific immunomodulator combining PD-L1⁷ checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with Bristol Myers Squibb Company (“BMS”).

• Pumitamig is currently being evaluated in seven pivotal trials across the ROSETTA clinical development program, with five new global clinical trials initiated in 2026 spanning triple-negative breast cancer (“TNBC”), colorectal cancer (“CRC”), gastric cancer, and non-small cell lung cancer (“NSCLC”), including two clinical trials in patients with unresectable stage III NSCLC, advanced disease and high PD-L1 expression (TPS ≥50%), respectively.
• A global Phase 2 clinical trial (ROSETTA Lung-107; NCT06841055) is being conducted to evaluate pumitamig in combination with docetaxel as a second-line treatment for patients with NSCLC. In October 2026, data from this trial were presented at the European Society for Medical Oncology (“ESMO”) Congress 2026. Pumitamig in combination with docetaxel showed encouraging antitumor activity with a manageable safety profile in patients with metastatic NSCLC post-chemoimmunotherapy. These data extend evidence for pumitamig’s NSCLC development program into the second-line setting where there remains high unmet medical need, representing the third global Phase 2 dataset in lung cancer.
• Global Phase 2 clinical trials (NCT06449209 and NCT06449222) are being conducted to evaluate pumitamig in combination with chemotherapy in patients with untreated extensive-stage small cell lung cancer (“ES-SCLC”) and in patients with small cell lung cancer (“SCLC”) that progressed after first- or second-line treatment and as a first- and second-line treatment for patients with locally advanced or metastatic TNBC, respectively. In October 2026, data from a subgroup analysis in patients with brain metastases from these trials were presented at the ESMO Congress 2026. Patients with TNBC or SCLC and brain metastases at baseline benefited clinically from pumitamig plus chemotherapy both systemically and intracranially, supporting pumitamig’s potential across difficult-to-treat tumor types and patient populations.
• BioNTech entered into a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed ADC sacituzumab govitecan as first-line treatment for patients with PD-L1 low or negative locally advanced or metastatic TNBC in the ROSETTA Breast-01 trial. Pending regulatory approval, this will be the first global Phase 3 clinical trial (NCT07173751) of pumitamig in combination with an ADC, reflecting the evolving standard of care in 1L TNBC.
• Pumitamig is also being evaluated in additional solid tumor indications, including first-line hepatocellular carcinoma (“HCC”), second-line glioblastoma (“GBM”), first-line PDAC and first-line renal cell carcinoma (“RCC”) in various Phase 1/2 and Phase 2 trials, both as monotherapy and in combination with standard of care.

BioNTech has several signal-seeking clinical trials ongoing evaluating pumitamig with the Company’s proprietary assets:

• A Phase 2 clinical trial (NCT06953089) is being conducted to evaluate elfetabart drozuntecan (BNT324/DB-1311) in combination with pumitamig. In October 2026, data from this trial were presented at the ESMO Congress 2026. Elfetabart drozuntecan in combination with pumitamig was well tolerated and encouraging antitumor activity was observed in patients across multiple tumor types. These data support the potential of pumitamig as a backbone in novel treatment combinations, furthering BioNTech’s combination strategy across multiple tumor types with high unmet medical need. They also help build the body of evidence for pumitamig in combination with ADCs that will inform potential registrational trials.
• A Phase 1/2 clinical trial (NCT06892548) is being conducted to evaluate elfetabart drozuntecan (BNT324/DB-1311) in combination with pumitamig in patients with advanced lung cancers. In September 2026, data from this trial were presented at the IASLC 2026 World Conference on Lung Cancer (“WCLC”). Elfetabart drozuntecan in combination with pumitamig showed encouraging early efficacy and a manageable safety profile in SCLC, across lines of therapy and dose levels. These were the first data in lung cancer for any investigational PD-(L)1xVEGF bispecific immunomodulator combined with an ADC candidate, underscoring BioNTech’s leadership in developing novel-novel combination treatment strategies.

Gotistobart (BNT316/ONC-392) is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. (“OncoC4”). 

• A global Phase 3 clinical trial (PRESERVE-003; NCT05671510) is ongoing to evaluate the efficacy and safety of gotistobart as monotherapy in patients with metastatic squamous NSCLC that progressed on previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment.
• • In September 2026, updated data from the stage 1 of this trial were presented at WCLC. Data demonstrated that gotistobart nearly doubled median overall survival (“OS”) versus chemotherapy in patients with squamous NSCLC who had progressed on PD-(L)1 inhibitors.

• • Gotistobart continues to show potential as a chemotherapy-free monotherapy in a hard-to-treat lung cancer setting.

• • Based on current event accrual projections, the first interim analysis from stage 2 of the Phase 3 clinical trial is expected in 2026. This will be assessed by the Independent Data Monitoring Committee (“IDMC”) to recommend whether to unblind the trial or continue to the next pre-planned interim analysis.

Antibody-Drug Conjugates

Trastuzumab pamirtecan (BNT323/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”). 

• Trastuzumab pamirtecan is being evaluated in two Phase 3 clinical trials in HR-positive, HER2-low metastatic breast cancer (NCT06018337) and HER2-expressing endometrial cancer (“EC”) (NCT06340568).
• The global Phase 3 clinical trial DYNASTY-Breast02 (NCT06018337) to evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low metastatic breast cancer met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) compared to investigator’s choice of chemotherapy. At this interim analysis for the secondary endpoint of OS, data were not mature. A higher rate of interstitial lung disease (“ILD”) was reported in this trial compared to prior trials with trastuzumab pamirtecan, with most cases being Grade 1 and 2. Severe and fatal events were reported in a small proportion of patients (Grade 3 to 5). Otherwise, the overall safety profile was consistent with prior clinical trials and no new safety signals were observed.
• The available efficacy and safety data, as of this data cut-off date, suggest that the potential benefit to patients would be limited in the context of the HR+/HER2-low metastatic breast cancer treatment landscape.
• BioNTech and DualityBio are currently discussing the totality of clinical data for trastuzumab pamirtecan across endometrial and breast cancer, within the context of the evolving treatment landscape, and areas of unmet medical need, and will determine the next steps.
• As part of this, BioNTech and DualityBio are discussing plans for a BLA submission and will update the markets accordingly.

mRNA Cancer Immunotherapies

Autogene cevumeran (BNT122/RO7198457) is an mRNA cancer immunotherapy candidate for individualized neoantigen-specific immunotherapy (“iNeST”) that is being developed in collaboration with Genentech, Inc. (“Genentech”), a member of the Roche Group (“Roche”).

• Early termination was initiated in a randomized Phase 2 clinical trial (NCT04486378) to evaluate autogene cevumeran as an adjuvant treatment of circulating tumor DNA, or ctDNA, positive, surgically resected Stage II (high risk)/Stage III CRC compared to watchful waiting after surgery and chemotherapy, which is the current standard of care for these high-risk patients.
• The Phase 2 clinical trial IMcode003 (NCT05968326) evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy in adjuvant PDAC is not affected and continues as planned. In August 2026, the trial completed enrollment.

BNT113 is an mRNA cancer immunotherapy candidate and based on BioNTech’s fully owned, off-the-shelf FixVac platform, encoding the two oncoproteins E6 and E7 that are frequently found in human papillomavirus type 16 positive (“HPV16+”) solid tumors.

• In October 2026, the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial (NCT04534205) were announced. The Phase 3 part of AHEAD-MERIT has dual primary endpoints, PFS and OS, providing complementary measures of clinical benefit. At the analysis for PFS, BNT113 in combination with pembrolizumab did not demonstrate a statistically significant improvement in PFS versus pembrolizumab alone. The IDMC has recommended that the clinical trial continues as planned to evaluate the second primary endpoint of OS to complete the assessment of the potential of this approach to help patients live longer. As immune-mediated anti-tumor effects build and deepen over time, the analysis of the second dual primary endpoint, OS, will be critical to fully assess the potential of this approach. Under the trial’s pre-specified statistical design, a statistically significant improvement in OS would establish a positive trial outcome, even if the PFS dual primary endpoint was not met. BioNTech remains blinded to ongoing trial data in accordance with the trial’s governance procedures.

Upcoming Investor and Analyst Events 

• BioNTech Fourth Quarter and Full Year 2026 Financial Results and Corporate Update: March 2, 2027

Conference Call and Webcast Information

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 3, 2026, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial results and provide a corporate update for the third quarter of 2026.

To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN number will be provided.

The slide presentation and audio of the webcast will be available via this link.

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the closing of the call and archived on the Company’s website for 30 days following the call.

About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech’s expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; BioNTech’s expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech’s expectations with respect to intellectual property; the impact of BioNTech’s collaboration and licensing agreements; BioNTech’s expectations with respect to developments in law, public policy, and international trade; BioNTech’s estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech’s expectations for upcoming scientific and investor presentations; and BioNTech’s expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech’s pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech’s other product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech’s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; expected changes to BioNTech’s leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended September 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de

Abbreviation Overview

ADC	Antibody-drug conjugate
BLA	Biologics license application
CRC	Colorectal cancer
ctDNA	Circulating tumor DNA
CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
EC	Endometrial cancer
ES-SCLC	Extensive-stage small cell lung cancer
GBM	Glioblastoma
HCC	Hepatocellular carcinoma
HER2	Human epidermal growth factor receptor 2
HPV16+	Human papillomavirus type 16 positive
HR	Hormone receptor
IDMC	Independent Data Monitoring Committee
ILD	Interstitial lung disease
iNeST	Individualized neoantigen-specific immunotherapy
IO	Immuno-oncology
mRNA	Messenger ribonucleic acid
NSCLC	Non-small cell lung cancer
OS	Overall survival
PDAC	Pancreatic ductal adenocarcinoma
PD-(L)1	Programmed cell death protein (death-ligand) 1
PFS	Progression-free survival
RCC	Renal cell carcinoma
SCLC	Small cell lung cancer
TPS	Tumor Proportion Score
TNBC	Triple-negative breast cancer
TROP2	Trophoblast cell surface antigen 2
VEGF-A	Vascular endothelial growth factor A

 

Interim Condensed Consolidated Statements of Profit or Loss

	Three months ended September 30,		Nine months ended September 30,
	2026	2025	2026	2025
(in millions €, except per share data)	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Revenues	1,289.2	1,518.9	1,512.9	1,962.5
Cost of sales	(103.3)	(148.3)	(271.7)	(308.5)
Research and development expenses	(748.1)	(564.8)	(1,856.1)	(1,599.5)
Sales and marketing expenses	(43.3)	(27.3)	(111.3)	(60.7)
General and administrative expenses	(135.2)	(121.2)	(415.8)	(345.8)
Other operating expenses	(163.6)	(729.5)	(443.7)	(884.7)
Other operating income	29.3	25.3	85.1	154.6
Operating profit / (loss)	125.0	(46.9)	(1,500.6)	(1,082.1)
Finance income	105.3	96.8	323.2	324.8
Finance expenses	(8.3)	(25.2)	(27.4)	(66.1)
Profit / (Loss) before tax	222.0	24.7	(1,204.8)	(823.4)
Income taxes	(37.5)	(53.4)	36.6	(7.7)
Net profit / (loss)	184.5	(28.7)	(1,168.2)	(831.1)
Earnings / (Loss) per share
Basic profit / (loss) per share	0.74	(0.12)	(4.63)	(3.45)
Diluted profit / (loss) per share	0.73	(0.12)	(4.63)	(3.45)

Interim Condensed Consolidated Statements of Financial Position

	September 30	December 31,
(in millions €)	2026	2025
Assets	(unaudited)
Non-current assets
Goodwill	376.0	367.9
Other intangible assets	1,201.6	1,606.0
Property, plant and equipment	1,000.9	1,080.9
Right-of-use assets	159.2	210.2
Contract assets	—	2.0
Other financial assets	1,727.3	2,554.2
Other assets	15.0	7.3
Deferred tax assets	20.0	13.5
Total non-current assets	4,500.0	5,842.0
Current assets
Inventories	64.9	110.7
Trade and other receivables	666.3	924.2
Contract assets	5.4	8.1
Other financial assets	4,457.6	7,201.8
Other assets	145.2	173.8
Income tax assets	124.3	52.6
Cash and cash equivalents	10,200.8	7,675.4
Assets held for sale	9.3	—
Total current assets	15,673.8	16,146.6
Total assets	20,173.8	21,988.6
Equity and liabilities
Equity
Share capital	259.0	259.0
Capital reserve	2,076.5	2,473.3
Treasury shares	(11.1)	(7.7)
Retained earnings	16,793.7	17,961.9
Other reserves	(1,406.4)	(1,462.3)
Total equity	17,711.7	19,224.2
Non-current liabilities
Lease liabilities, loans and borrowings	255.4	215.2
Other financial liabilities	108.9	94.9
Provisions	64.6	35.5
Contract liabilities	0.7	88.0
Other liabilities	117.1	104.2
Deferred tax liabilities	82.6	84.3
Total non-current liabilities	629.3	622.1
Current liabilities
Lease liabilities, loans and borrowings	104.4	52.2
Trade payables and other payables	523.1	534.9
Other financial liabilities	141.2	351.7
Income tax liabilities	13.2	65.6
Provisions	244.2	145.3
Contract liabilities	623.6	754.9
Other liabilities	181.1	237.7
Liabilities related to assets held for sale	2.0	—
Total current liabilities	1,832.8	2,142.3
Total liabilities	2,462.1	2,764.4
Total equity and liabilities	20,173.8	21,988.6

Interim Condensed Consolidated Statements of Cash Flows

	Three months ended September 30,		Nine months ended September 30,
	2026	2025	2026	2025
(in millions €)	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Operating activities
Net profit / (loss)	184.5	(28.7)	(1,168.2)	(831.1)
Income taxes	37.5	53.4	(36.6)	7.7
Profit / (Loss) before tax	222.0	24.7	(1,204.8)	(823.4)
Adjustments to reconcile profit / (loss) before tax to net cash flows:
Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets	332.3	124.2	719.7	218.0
Share-based payment expenses	20.0	27.9	63.7	82.1
Net foreign exchange differences	(3.2)	(24.1)	14.3	36.4
Gain on disposal of property, plant and equipment	(0.1)	(1.3)	(1.1)	(1.7)
Finance income excluding foreign exchange differences	(96.3)	(96.8)	(301.9)	(324.8)
Finance expense excluding foreign exchange differences	8.3	2.6	27.4	17.1
Government and similar grants	(13.2)	(10.5)	(45.3)	(43.5)
Other non-cash income	—	—	—	(15.0)
Working capital adjustments:
Decrease / (Increase) in trade and other receivables, contract assets and other assets	(489.1)	897.1	308.1	1,005.5
Decrease in inventories	33.5	5.1	43.7	61.7
Decrease in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions	(197.6)	(242.5)	(344.8)	(314.9)
Interest received and realized gains from cash and cash equivalents	78.0	83.5	235.4	275.2
Interest paid and realized losses from cash and cash equivalents	(2.8)	(2.4)	(8.4)	(8.2)
Income tax paid, net	(33.7)	(9.6)	(91.4)	(36.7)
Share-based payments	(4.2)	(4.2)	(19.2)	(19.3)
Government and similar grants received	16.3	7.0	64.3	38.0
Net cash flows from / (used in) operating activities	(129.8)	780.7	(540.3)	146.5
Investing activities
Purchase of property, plant and equipment	(33.6)	(35.9)	(145.0)	(111.9)
Proceeds from sale of property, plant and equipment	1.5	2.9	6.5	3.9
Purchase of intangible assets	(14.9)	(2.7)	(37.8)	(575.0)
Acquisition of subsidiaries and businesses, net of cash acquired	(31.8)	—	(31.8)	(78.5)
Investment in other financial assets	(1,504.9)	(2,869.0)	(5,111.0)	(7,046.7)
Proceeds from maturity of other financial assets	2,391.4	1,979.4	8,677.3	8,065.3
Net cash flows from / (used in) investing activities	807.7	(925.3)	3,358.2	257.1
Financing activities
Proceeds from loans and borrowings	52.9	—	129.1	—
Repayment of loans and borrowings	—	(1.2)	(5.9)	(9.4)
Payments related to lease liabilities	(11.2)	(10.3)	(34.4)	(29.2)
Share repurchase program	(274.3)	—	(403.5)	—
Net cash flows used in financing activities	(232.6)	(11.5)	(314.7)	(38.6)
Net increase / (decrease) in cash and cash equivalents	445.3	(156.1)	2,503.2	365.0
Change in cash and cash equivalents resulting from exchange rate differences	2.0	(21.5)	(4.7)	(28.4)
Change in cash and cash equivalents resulting from other valuation effects	12.5	1.0	26.9	(5.6)
Cash and cash equivalents at the beginning of the period	9,741.0	10,269.5	7,675.4	9,761.9
Cash and cash equivalents as of September 30	10,200.8	10,092.9	10,200.8	10,092.9

Certain prior period lines were aggregated to conform to current period presentation and to improve readability.

Non-IFRS Reconciliation

Non-IFRS Reconciliation for the three months ended September 30, 2026
		non-IFRS adjustments (unaudited)
(in millions €, except per share data)	IFRS Results	Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	Adjusted Results
	(unaudited)					(unaudited)
Cost of sales	(103.3)	—	11.4	—	—	(91.9)
Research and development expenses	(748.1)	—	169.6	—	—	(578.5)
Other operating expenses	(163.6)	13.5	42.2	19.7	—	(88.2)
Operating profit	125.0	13.5	223.2	19.7	—	381.4
Profit before tax	222.0	13.5	223.2	19.7	—	478.4
Net profit1	184.5	13.5	223.2	19.7	—	440.9
Earnings per share
Basic profit per share	0.74					1.76
Diluted profit per share	0.73					1.76

¹ Tax effects are not considered as part of BioNTech’s non-IFRS adjustments.

Non-IFRS Reconciliation for the three months ended September 30, 2025
		non-IFRS adjustments (unaudited)
(in millions €, except per share data)	IFRS Results	Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	Adjusted Results
	(unaudited)					(unaudited)
Research and development expenses	(564.8)	—	85.4	—	—	(479.4)
Other operating expenses	(729.5)	678.5	—	17.3	—	(33.7)
Operating profit / (loss)	(46.9)	678.5	85.4	17.3	—	734.3
Profit before tax	24.7	678.5	85.4	17.3	—	805.9
Net profit / (loss)	(28.7)	678.5	85.4	17.3	—	752.5
Earnings / (Loss) per share
Basic profit / (loss) per share	(0.12)					3.12
Diluted profit / (loss) per share	(0.12)					3.11

¹ Tax effects are not considered as part of BioNTech’s non-IFRS adjustments.

Non-IFRS Reconciliation for the nine months ended September 30, 2026
		non-IFRS adjustments (unaudited)
(in millions €, except per share data)	IFRS Results	Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	Adjusted Results
	(unaudited)					(unaudited)
Cost of sales	(271.7)	—	11.4	—	—	(260.3)
Research and development expenses	(1,856.1)	—	273.4	—	—	(1,582.7)
Other operating expenses	(443.7)	13.5	129.2	124.8	—	(176.2)
Operating loss	(1,500.6)	13.5	414.0	124.8	—	(948.3)
Loss before tax	(1,204.8)	13.5	414.0	124.8	—	(652.5)
Net loss1	(1,168.2)	13.5	414.0	124.8	—	(615.9)
Loss per share
Basic and diluted loss per share	(4.63)					(2.44)

¹ Tax effects are not considered as part of BioNTech’s non-IFRS adjustments.

Non-IFRS Reconciliation for the nine months ended September 30, 2025
		non-IFRS adjustments (unaudited)
(in millions €, except per share data)	IFRS Results	Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	Adjusted Results
	(unaudited)					(unaudited)
Research and development expenses	(1,599.5)	—	85.4	—	—	(1,514.1)
Other operating expenses	(884.7)	678.5	10.0	45.1	—	(151.1)
Other operating income	154.6	—	—	—	(15.0)	139.6
Operating loss	(1,082.1)	678.5	95.4	45.1	(15.0)	(278.1)
Loss before tax	(823.4)	678.5	95.4	45.1	(15.0)	(19.4)
Net loss1	(831.1)	678.5	95.4	45.1	(15.0)	(27.1)
Loss per share
Basic and diluted loss per share	(3.45)					(0.11)

¹ Tax effects are not considered as part of BioNTech’s non-IFRS adjustments.

• Net revenues of Euro 1,896 million, up 7% versus prior year (up 10% at constant currency⁽¹⁾)

• Operating profit (EBIT)⁽¹⁾ of Euro 563 million, with Operating profit (EBIT) margin of 29.7%, up 12% versus prior year (up 23% at constant currency)
• Net profit of Euro 431 million and diluted EPS at Euro 2.44
• EBITDA⁽¹⁾ of Euro 753 million, with EBITDA margin of 39.7%, up 12% versus prior year (up 20% at constant currency)
• Industrial free cash flow⁽¹⁾⁽²⁾ of Euro 567 million, up 43% versus the prior year

“Uniqueness, innovation and focus: three key factors to keep the promises of our last Capital Markets Day. Deliveries of our F80 supercar and personalizations, led by the Ferrari 296 Speciale family, support our robust financial growth and reflect our clients’ ever-deepening desire to make each Ferrari uniquely their own. Building on this solid foundation, we are further raising our full-year guidance,” said Benedetto Vigna, CEO of Ferrari. “Our order book now reaches into 2028, and we still have two more launches to come this year. In addition, we continue to create engaging events around the world to further tighten the bonds with our clients and partners across Racing, Sports Cars and Lifestyle”.

For the three months ended				(In Euro million,	For the nine months ended
September 30,				unless otherwise stated)	September 30,
2026	2025	Change			2026	2025	Change
1,896	1,766	130	7%	Net revenues	5,682	5,344	338	6%
563	503	60	12%	Operating profit (EBIT)	1,716	1,597	119	7%
29.7%	28.4%	130 bps		Operating profit (EBIT) margin	30.2%	29.9%	30 bps
431	382	49	13%	Net profit	1,307	1,219	88	7%
2.45	2.14	0.31	14%	Basic EPS (in Euro)	7.40	6.83	0.57	8%
2.44	2.14	0.30	14%	Diluted EPS (in Euro)	7.39	6.82	0.57	8%
753	670	83	12%	EBITDA	2,230	2,072	158	8%
39.7%	37.9%	180 bps		EBITDA margin	39.2%	38.8%	40 bps
567	396(2)	171	43%	Free Cash Flow from Industrial Activities	1,496	1,214(2)	282	23%

Maranello (Italy), November 3, 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) today announces its consolidated preliminary unaudited results⁽³⁾ for the third quarter and nine months ended September 30, 2026.

Business dynamics in Q3 2026

Within Sports Cars, the business performance continued to benefit from the enrichment of the product mix and the increased contribution of personalizations. In the quarter, deliveries were 3,368 units as Ferrari continued to execute its planned model change-over. Deliveries of the Amalfi, the 296 Speciale, the 12Cilindri Spider and the Purosangue increased, the 849 Testarossa and the 296 Speciale Aperta continued their ramp-up phase, and the 849 Testarossa Spider commenced deliveries. The Roma Spider, the 296 GTS and the SF90 XX family phased out. Shipments of the F80 progressed in line with plans.

Following the launch of the 12Cilindri Manuale at the beginning of July, client engagement experiences continued in the quarter, with the record-setting auction of the Ferrari Luce “Chassis 0” at Monterey Car Week and the digital debut of the track model 296 GT3 Modificata.

Racing revenues increased in the quarter, mainly driven by higher sponsorships and a positive contribution from the rental of engines to other Formula 1 racing teams. The quarter also reflected Ferrari’s continued competitiveness in motorsport, with podium finishes recorded by both Scuderia Ferrari in Formula 1 and the 499P Hypercar in the FIA World Endurance Championship. In the quarter, the Hypersail project made further progress, including the flying monohull entering its final construction phase.

Lifestyle initiatives were rich in the quarter, including the capsule collection launched for the Monza Grand Prix, the continued evolution of tailored experiences offered through Casa Ferrari and the Fan Zones, as well as the launch of the Sketch Body, a distinctive project within the Collectibles offer that celebrates the intersection of art, innovation and heritage.

Total net revenues

Net revenues for Q3 2026 were Euro 1,896 million, up 7% (up 10% at constant currency). Revenues from Cars and spare parts were Euro 1,586 million, up 7%, thanks to a richer sports cars mix and higher personalizations. Sponsorship, commercial and brand revenues reached Euro 220 million, up 4%, mainly attributable to higher sponsorships and lifestyle activities, partially offset by lower Formula 1 commercial revenues linked to the prior year Formula 1 ranking. Other revenues also grew in the quarter, mostly reflecting rental of engines to other Formula 1 racing teams. Foreign exchange impact, net of currency hedges, resulted in a negative effect primarily due to the US Dollar and the Japanese Yen.

For the three months ended				(Euro million)	For the nine months ended
September 30,					September 30,
		Change					Change
2026	2025	at constant			2026	2025	at constant
		currency					currency
1,586	1,479	7%	10%	Cars and spare parts(4)	4,771	4,522	6%	8%
220	211	4%	7%	Sponsorship, commercial and brand(5)	647	607	7%	8%
90	76	18%	17%	Other(6)	264	215	22%	24%
1,896	1,766	7%	10%	Total net revenues	5,682	5,344	6%	9%

Operating profit (EBIT) and EBITDA

Q3 2026 Operating profit (EBIT) was Euro 563 million, up 12% versus the prior year (up 23% at constant currency) and with an Operating profit (EBIT) margin of 29.7%. The increase was mostly attributable to a positive product mix – mainly supported by the F80 – and higher personalizations. This was partially offset by higher depreciation and amortization, in line with the start of production of new models and increased marketing expenses. Q3 2026 EBITDA reached Euro 753 million, up 12% versus the prior year (up 20% at constant currency) and with an EBITDA margin of 39.7%.

For the three months ended					(Euro million)	For the nine months ended
September 30,						September 30,
		Change							Change
2026	2025	at constant					2026	2025		at constant
		currency								currency
753	670	12%	20%	EBITDA			2,230	2,072	8%		13%
563	503	12%	23%	Operating profit (EBIT)			1,716	1,597	7%		15%

The decrease in net financial expenses for the quarter was mostly driven by a positive net foreign exchange effect. The effective tax rate⁽⁷⁾ in the quarter was 23.0%, mainly reflecting the estimate of the benefit attributable to the new Patent Box. As a result, the Net profit in the quarter increased to Euro 431 million and the diluted earnings per share reached Euro 2.44, compared to Euro 2.14 in Q3 2025.

Industrial free cash flow in the quarter was strong at Euro 567 million, sustained by profitability and a positive change in working capital, partially offset by capital expenditures⁽⁸⁾.

Net Industrial Cash⁽¹⁾ as of September 30, 2026 was Euro 219 million, compared to a Net Industrial Debt position of Euro 131 million as of June 30, 2026, also reflecting the share repurchases for Euro 173 million.

2026 guidance further upgraded, based on the updated assumptions:

• Stronger personalizations than initially expected
• Lower than anticipated currency headwinds, net of hedges
• Second place in the Formula 1 Championship

Confirmed the below, compared with 2025:

• Significant model change-over to shape the year and positive product mix
• Higher racing and lifestyle revenues
• Increased brand investments, as well as racing and digital expenses
• Higher D&A in line with start of production of new models

Our guidance is based on current visibility on the Middle East crisis effects.

(€B, unless otherwise stated)	UPGRADED 2026 GUIDANCE	PREVIOUS 2026 GUIDANCE	2025
NET REVENUES	~7.65	~7.60	7.15
ADJ. EBITDA (margin %)	≥3.00 ≥39.2%	≥2.97 ≥39.0%	2.77 38.8%
ADJ. OPERATING PROFIT (EBIT) (margin %)	≥2.285 ≥29.8%	≥2.26 ≥29.5%	2.11 29.5%
ADJ. DILUTED EPS (€)	≥9.85(9)	≥9.68(10)	8.96(11)
INDUSTRIAL FCF	Up to 1.65	≥1.55	1.54

Subsequent events:

• From October 1, 2026, to October 30, 2026, the Company purchased 176,262 common shares for total consideration of €61.5 million. The share repurchases were made under the third tranche of the multi-year share buyback program of approximately €3.5 billion expected to be executed by 2030, as announced during the Capital Markets Day held in October 2025. At October 30, 2026, the Company held in treasury 2,038,689 common shares, corresponding to 1.15% of issued common shares and 0.87% of issued share capital (including special voting shares).

About Ferrari
Ferrari is one of the world’s leading luxury brands, encompassing racing, sports cars and lifestyle. In each of these three souls, the Prancing Horse is a symbol of exclusivity, innovation and cutting-edge performance. The brand’s heritage and global recognition are closely associated with its Formula 1 racing team, Scuderia Ferrari, the most successful in the sport’s history. Since the inaugural World Championship in 1950, Scuderia Ferrari has claimed 16 Constructors’ and 15 Drivers’ world titles. From its home in Maranello, Italy, Ferrari designs, engineers, and produces some of the world’s most iconic and recognisable luxury sports cars, sold in over 60 markets worldwide. In lifestyle, Ferrari designs and creates a selection of personal luxury goods, collectibles and experiences that embody the brand’s elevated style and passion.

Forward Looking Statements
In this document, unless otherwise specified, the terms “we”, “our”, “us”, the “Group”, the “Company” and “Ferrari” refer to Ferrari N.V., individually or together with its subsidiaries, as the context may require. This document, and in particular the section entitled “2026 Guidance”, contain forward-looking statements. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “continue”, “on track”, “successful”, “grow”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, “guidance” and similar expressions. Forward-looking statements are not guarantees of future performance. Rather, they are based on the Group’s current expectations and projections about future events and, by their nature, are subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them. Actual results may differ materially from those expressed in such statements as a result of a variety of factors, including: our ability to preserve and enhance the value of the Ferrari brand; our ability to attract and retain qualified personnel; the success of our racing activities; our ability to keep pace with advances in high performance automotive technology, and meet the challenges and costs of continually integrating leading-edge innovations into our car portfolio over time, while continuing to create distinctive and desirable designs for our new models; increases in costs, including as a result of increasingly stringent fuel economy, emissions and safety standards, disruptions of supply or shortages of components and raw materials; our ability to successfully carry out our controlled volume and growth strategy, while increasing our presence in growth market countries; changes in general economic conditions (including changes in the markets in which we operate) and changes in demand for luxury goods, including high performance luxury cars, which is volatile; macro events, pandemics and conflicts, including the ongoing conflicts in Ukraine and the Middle East region, and the related issues potentially impacting sourcing and transportation; trading policies and tariffs; competition in the luxury performance automobile industry; changes in client preferences and automotive trends; our ability to preserve the value of our cars over time and our relationship with the automobile collector and enthusiast community; disruptions at our manufacturing facilities in Maranello and Modena; climate change and other environmental impacts, as well as an increased focus of regulators and stakeholders on environmental matters; our ability to maintain the functional and efficient operation of our information technology systems and to defend against the risk of cyberattacks; the ability of our current management team to operate and manage effectively, and the reliance upon a number of key members of executive management and employees; the performance of our dealer network on which we depend for sales and services; product warranties, product recalls and liability claims; the sponsorship and commercial revenues and expenses of our racing activities, as well as the popularity of motor sports more broadly; the performance of our lifestyle activities; our ability to protect our intellectual property rights and to avoid infringing the intellectual property rights of others; changes in tax or fiscal policies and regulatory, political and labor conditions in the jurisdictions in which we operate; our continued compliance with customs regulations of various jurisdictions; labor relations and collective bargaining agreements; our ability to ensure that our employees, agents and representatives comply with applicable law and regulations; exchange rate fluctuations, interest rate changes, credit risk and other market risks; our ability to service and refinance our debt; our ability to provide or arrange for adequate access to financing for our clients and dealers, and associated risks; the adequacy of our insurance coverage to protect us against potential losses; potential conflicts of interest due to director and officer overlaps with our largest shareholders, and other factors discussed elsewhere in this document.

The Group expressly disclaims and does not assume any liability in connection with any inaccuracies in any of the forward-looking statements in this document or in connection with any use by any third party of such forward-looking statements. Any forward-looking statements contained in this document speak only as of the date of this document and the Company does not undertake any obligation to update or revise publicly forward-looking statements. Further information concerning the Group and its businesses, including factors that could materially affect the Company’s financial results, is included in the Company’s reports and filings with the U.S. Securities and Exchange Commission, the AFM and CONSOB.

For further information:
Ferrari Media & PR
tel.: +39 0536 241053
Email: media@ferrari.com

Investor Relations
tel.: +39 0536 241395
Email: ir@ferrari.com

www.ferrari.com

Earnings call

On November 3, 2026, at 3:00 p.m. CET, management will hold a conference call to present the Q3 2026 results to financial analysts and institutional investors. Please note that registering in advance is required to access the conference call details. The call can be followed live and a recording will subsequently be available on the Group’s website https://www.ferrari.com/en-EN/corporate/investors. The supporting document will be made available on the website prior to the call.

Appendix and non-GAAP financial measures

Operations are monitored through the use of various non-GAAP financial measures that may not be comparable to other similarly titled measures of other companies. Accordingly, investors and analysts should exercise appropriate caution in comparing these supplemental financial measures to similarly titled financial measures reported by other companies.

We believe that these supplemental financial measures provide comparable measures of financial performance which then facilitate management’s ability to identify operational trends, as well as make decisions regarding future spending, resource allocations and other operational decisions.

Certain totals in the tables included in this document may not add due to rounding.

Shipments^(12)(13)

For the three months ended			Shipments	For the nine months ended
September 30,			(units)	September 30,
2026	2025	Change (units)		2026	2025	Change (units)
1,487	1,449	38	EMEA	4,801	4,796	5
1,050	1,045	5	Americas	2,867	3,060	(193)
143	248	(105)	Mainland China, Hong Kong and Taiwan	583	759	(176)
688	659	29	Rest of APAC	1,919	1,873	46
3,368	3,401	(33)	Total Shipments	10,170	10,488	(318)

Key performance metrics and reconciliations of NON-GAAP financial measures

For the three months ended		(Euro million)	For the nine months ended
September 30,			September 30,
2026	2025		2026	2025
1,896	1,766	Net revenues	5,682	5,344
902	882	Cost of sales	2,711	2,586
173	160	Selling, general and administrative costs	522	469
251	222	Research and development costs	714	680
8	2	Other expenses/(income), net	27	20
1	3	Result from investments	8	8
563	503	Operating profit (EBIT)	1,716	1,597
4	13	Financial expenses/(income), net	19	34
559	490	Profit before taxes	1,697	1,563
128	108	Income tax expenses	390	344
23.0%	22.0%	Effective tax rate	23.0%	22.0%
431	382	Net profit	1,307	1,219
2.45	2.14	Basic EPS (€)	7.40	6.83
2.44	2.14	Diluted EPS (€)	7.39	6.82
753	670	EBITDA	2,230	2,072
738	658	of which EBITDA (Industrial activities only)	2,187	2,040

Total net revenues, EBITDA and Operating profit (EBIT) at constant currency eliminate the effects of changes in foreign currency (transaction and translation) and of foreign currency hedges.

For the three months ended		(Euro million)	For the nine months ended
September 30,			September 30,
	2026			2026
2026	at constant		2026	at constant
	currency			currency
1,586	1,588	Cars and spare parts	4,771	4,835
220	220	Sponsorship, commercial and brand	647	647
90	89	Other	264	268
1,896	1,897	Total net revenues	5,682	5,750

For the three months ended		(Euro million)	For the nine months ended
September 30,			September 30,
	2026			2026
2026	at constant		2026	at constant
	currency			currency
753	759	EBITDA	2,230	2,283
563	569	Operating profit (EBIT)	1,716	1,769

EBITDA is defined as net profit before income tax expense, financial expenses/(income), net and amortization and depreciation. Adjusted EBITDA is defined as EBITDA as adjusted for certain income and costs, which are significant in nature, expected to occur infrequently, and that management considers not reflective of ongoing operational activities.

For the three months ended			(Euro million)	For the nine months ended
September 30,				September 30,
2026	2025	Change		2026	2025	Change
431	382	49	Net profit	1,307	1,219	88
128	108	20	Income tax expense	390	344	46
4	13	(9)	Financial expenses/(income), net	19	34	(15)
190	167	23	Amortization and depreciation	514	475	39
753	670	83	EBITDA	2,230	2,072	158
–	–	–	Adjustments	–	–	–
753	670	83	Adjusted EBITDA	2,230	2,072	158

Adjusted Operating profit or Adjusted Earnings Before Interest and Taxes or Adjusted EBIT represents Operating profit (EBIT) as adjusted for certain income and costs which are significant in nature, expected to occur infrequently, and that management considers not reflective of ongoing operational activities.

For the three months ended			(Euro million)	For the nine months ended
September 30,				September 30,
2026	2025	Change		2026	2025	Change
563	503	60	Operating profit (EBIT)	1,716	1,597	119
–	–	–	Adjustments	–	–	–
563	503	60	Adjusted Operating profit (EBIT)	1,716	1,597	119

Adjusted Net profit represents net profit as adjusted for certain income and costs (net of tax effect) which are significant in nature, expected to occur infrequently, and that management considers not reflective of ongoing operational activities.

For the three months ended			(Euro million)	For the nine months ended
September 30,				September 30,
2026	2025	Change		2026	2025	Change
431	382	49	Net profit	1,307	1,219	88
–	–	–	Adjustments	–	–	–
431	382	49	Adjusted net profit	1,307	1,219	88

Basic and diluted EPS⁽¹⁴⁾ are determined as per the table here below. Adjusted EPS represents EPS as adjusted for certain income and costs (net of tax effect) which are significant in nature, expected to occur infrequently, and that management considers not reflective of ongoing operational activities.

For the three months ended			(Euro million, unless otherwise stated)	For the nine months ended
September 30,				September 30,
2026	2025	Change		2026	2025	Change
430	381	49	Net profit attributable to the owners of the Company	1,305	1,217	88
175,730	178,148		Weighted average number of common shares (thousand)	176,309	178,340
2.45	2.14	0.31	Basic EPS (in Euro)	7.40	6.83	0.57
–	–	–	Adjustments	–	–	–
2.45	2.14	0.31	Adjusted basic EPS (in Euro)	7.40	6.83	0.57
175,931	178,348		Weighted average number of common shares for diluted earnings per common share (thousand)	176,510	178,540
2.44	2.14	0.30	Diluted EPS (in Euro)	7.39	6.82	0.57
–	–	–	Adjustments	–	–	–
2.44	2.14	0.30	Adjusted diluted EPS (in Euro)	7.39	6.82	0.57

Capex and R&D

For the three months ended		(Euro million)	For the nine months ended
September 30,			September 30,
2026	2025		2026	2025
226	230	Capital expenditures(8)	715	693
118	106	of which capitalized development costs(15) (A)	352	326
151	138	Research and development costs expensed (B)	451	444
269	244	Total research and development (A+B)	803	770
100	84	Amortization of capitalized development costs (C)	263	236
251	222	Research and development costs as recognized in the consolidated income statement (B+C)	714	680

Free Cash Flow and Free Cash Flow from Industrial Activities are two of management’s primary key performance indicators to measure the Group’s performance. Free Cash Flow is defined as consolidated cash flows from operating activities less investments in property, plant and equipment (excluding right-of-use assets recognized during the period in accordance with IFRS 16 — Leases), and intangible assets. Free Cash Flow from Industrial Activities is defined as Free Cash Flow adjusted to exclude the operating cash flow from our financial services activities (Free Cash Flow from Financial Services Activities). Free Cash Flow from Financial Services Activities is defined as cash flows from operating activities of our financial services activities less investments in property, plant and equipment (excluding right-of-use assets recognized during the period in accordance with IFRS 16 — Leases), intangible assets of our financial services activities.

For the three months ended		(Euro million)	For the nine months ended
September 30,			September 30,
2026	2025		2026	2025
737	588	Cash flow from operating activities	2,037	1,830
(226)	(230)	Investments in property, plant and  equipment and intangible assets	(715)	(693)
511	358	Free Cash Flow	1,322	1,137
(56)	(38)	Free Cash Flow from Financial Services Activities	(174)	(77)
567	396	Free Cash Flow from Industrial Activities(16)	1,496	1,214

Net Industrial (Debt)/Cash, defined as total Debt less Cash and Cash Equivalents (Net (Debt)/Cash), further adjusted to exclude the debt and cash and cash equivalents related to our financial services activities (Net (Debt)/Cash of Financial Services Activities). Net Debt of Financial Services Activities is defined as debt of our financial services activities less cash and cash equivalents of our financial services activities. The Net Debt of Financial Services Activities primarily relates to our asset-backed financing (securitizations) of the receivables generated by our financial services activities in the United States.

(Euro million)	Sept. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025
Debt	(3,122)	(3,166)	(2,929)	(2,884)
of which lease liabilities as per IFRS 16	(156)	(157)	(161)	(162)
Cash and Cash Equivalents	1,729	1,486	1,857	1,467
Net (Debt)/Cash	(1,393)	(1,680)	(1,072)	(1,417)
Net (Debt)/Cash of Financial Services Activities	(1,612)	(1,549)	(1,460)	(1,385)
Net Industrial (Debt)/Cash	219	(131)	388	(32)

---

¹   The term EBIT is used as a synonym for Operating profit. Adjusted metrics equaled the reported ones, since there were no adjustments impacting EBITDA, EBITDA margin, EBIT, EBIT margin, Net profit, Basic EPS and Diluted EPS in the periods presented. Refer to specific paragraph on non-GAAP financial measures.

²    Free cash flow from industrial activities for the three and nine months ended September 30, 2025 have been re-presented to include Euro 32 million mainly related to withholding taxes, which were paid in the third quarter.

³   These results have been prepared in accordance with the IFRS Accounting Standards (“IFRS Accounting Standards”) as issued by the International Accounting Standards Board (“IASB”) as well as IFRS Accounting Standards as adopted by the European Union

⁴       Includes net revenues generated from shipments of our cars, any personalization generated on these cars, as well as sales of spare parts

⁵       Includes net revenues earned by our racing teams (mainly in the Formula 1 World Championship and the World Endurance Championship) through sponsorship agreements and our share of the Formula 1 World Championship commercial revenues, as well as net revenues generated through the Ferrari brand, including lifestyle collections, merchandising, licensing and royalty income

⁶       Primarily relates to financial services activities, management of the Mugello racetrack and other sports-related activities, as well as net revenues generated from the rental of engines to other Formula 1 racing teams

⁷    In Q3 2026 the effective tax rate benefits from the new Patent Box regime regulated by Law Decree No. 146 and effective from October 22, 2021, which provides for a 110% super tax deduction for costs relating to eligible intangible assets

⁸   Capital expenditures excluding right-of-use assets recognized during the period in accordance with IFRS 16 – Leases

⁹    Calculated using the weighted average diluted number of common shares as of September 30, 2026 (176,510 thousand)

¹⁰  Calculated using the weighted average diluted number of common shares as of June 30, 2026 (176,804 thousand)

¹¹  Calculated using the weighted average diluted number of common shares as of December 31, 2025 (178,321 thousand)

¹²  Excluding strictly limited racing cars (such as the XX Programme and the 499P Modificata), one-off and pre-owned cars, and other special sales

¹³  EMEA includes: Italy, UK, Germany, Switzerland, France, Middle East (includes the United Arab Emirates, Saudi Arabia, Bahrain, Lebanon, Qatar, Oman and Kuwait), Africa and European markets not separately identified; Americas includes: United States of America, Canada, Mexico, the Caribbean and Central and South America; Rest of APAC mainly includes: Japan, Australia, Singapore, Indonesia, South Korea, Thailand, India and Malaysia

¹⁴  The weighted average number of common shares for diluted earnings per share was increased to take into consideration the theoretical effect of the potential common shares that would be issued for outstanding share-based awards granted by the Group (assuming 100 percent of the target awards vested)

¹⁵  Capitalized as intangible assets

¹⁶ Free cash flow from industrial activities for the three and nine months ended September 30, 2025 has been re-presented to include Euro 32 million mainly related to withholding taxes, which were paid in the third quarter. Starting from the three and six months ended June 30, 2026 the free cash flow from industrial activities excludes withholding taxes.

Attachment

• 2026_11_03 – Ferrari Q3 2026 Results Press Release

COSTA MESA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) announced today that Suman Mookerji, senior vice president and chief financial officer, will participate in the upcoming RBC Capital Markets Global Industrials Conference on November 17, 2026. Institutional investors are welcome to contact RBC Capital Markets to arrange one-on-one meetings with management.

About Ducommun Incorporated

Ducommun Incorporated delivers value-added innovative products, aftermarket and manufacturing solutions to customers in the aerospace, defense and space markets and aspires to contribute to the advancement of those industries. Founded in 1849, the Company specializes in two core areas — Electronic Systems and Structural Systems — to produce complex products and components for commercial aircraft platforms and mission-critical military and space programs. For more information, visit Ducommun.com.

Contacts
Suman Mookerji, Senior Vice President & Chief Financial Officer
657.335.3665, SMookerji@ducommun.com